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ABSTRACT

EXPANDING MONOAMINE TRANSPORTERS PHARMACOLOGY USING
CALCIUM CHANNELS

By Iwona Ruchala, Ph.D.

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University School of Medicine.

Virginia Commonwealth University, 2017

Dissertation Director: Jose M. Eltit, Ph.D.
Assistant Professor of Physiology and Biophysics

Research in drug development meets many challenges including lengthy, complex and
costly procedures to identify novel pharmacotherapies. In our lab, we developed a method for
fast screening of small molecules that interact with monoamine transports – dopamine and
serotonin (DAT, SERT).

These membrane proteins play important roles in brain

neurotransmission responsible for cognition, motion and pleasure. Dysfunction in dopaminergic
and serotonergic systems result in neurological disorders such as depression, Attention Deficit
Hyperactivity Disorder (ADHD), schizophrenia and addiction.
DAT and SERT are responsible for uptake of dopamine (DA) or serotonin (5HT) into the
synapse and they limit neurotransmitter signaling. Drugs that mimic or antagonize actions of
endogenous neurotransmitters (DA and 5HT) increase the concentrations of DA and/or 5HT

either by blocking the transporter (blockers) or by competing uptake with neurotransmitter
(substrate). The uptake of substrates is associated to an inward current that depolarizes the cell
membrane. Voltage-gated calcium channels (CaV) can respond to small changes in membrane
potential. In our method, we combined permanent cell line expressing the human dopamine
transporter (hDAT) or the human serotonin transporter (hSERT) (FlpIn TREx expression
system) with transient transfection of CaV. This system works as a tightly electrically coupled
system. Cells challenged with substrate of the transports produce detectable Ca2+ signal while
monoamine transporter blockers can inhibit these Ca2+ signals. The novelty of this method relies
on the ability to discriminate between substrate and blockers of monoamine transporters.
Preliminary experiments measuring our optimized cell system in a Flex Station 3 plate reader
suggest that the co-expression of a voltage-gated Ca2+ channel, a monoamine transporter and a
genetically encoded Ca2+ sensor constitute a rapid screening biosensor to identify active drugs at
monoamine transporters.
Our novel methodology can rapidly assess drug-effect profile on monoamine transporters
and benefit development of new psychotherapeutics for treatment of mental illnesses. It can also
be used to characterize mechanism of action of emerging drug of abuse, as well as to discover
small molecules with novel drug-effect profile useful in basic neuroscience research.

1.

1.1

Chapter one: Introduction

Psychoactive drugs history of use

Psychoactive substances are all chemical compounds that can alter homeostasis of the
central nervous system. They have been used throughout the centuries to influence mood,
perception, consciousness and behavior. [1] Traditionally, mind-altering plants were used in ritual
ceremonies, cults and early medicine. Usage of such substances played less entertaining roles than
nowadays, instead they played the important role of making the tribe coherent thus implicated in
the survival of the tribe. [2] The archaeological evidence shows use of psychoactive drug plants
already in the prehistoric times – in prepottery Neolithic times, i.e. 8000BC. [3] The earliest use
of psychotropic substances was Amanita muscaria which caused hallucination, hypersensation
and a perception of time standing still. [4] Although Amanita is no longer used as a psychoactive
drug there are other psychoactive substances that were known in the ancient time and are still
used nowadays – opium, cannabis, alcohol, nicotine and cocaine.
Through the centuries, psychoactive substances were used in a number of ways, including
the military, during rituals and spirituals, for anesthesia and pain management and to threat
mental disorders. Nowadays, the substance misuse or abuse is a major public health problem and
a huge burden to societies throughout the world. [1] In the scale developed to determine harmful
effects of the drugs Nutt et al. [5] show three categories of harm. Category one consist of acute
toxic effect of drugs as well as chronic physical harm, which results as consequence of repeated
usage – e.g. drug like heroin can cause sudden death from respiratory depression [6] or repeated
stimulant intake causes psychosis [7]. The second category is predisposition of the drug to induce
dependence and the third category is drug effect on the whole society. The scale goes from 0-3
1

where 3 represents “extreme risk”. This scale shows some differences in comparison to the
current “Class in Misuse of Drug Act” (Figure 1.1).

Figure 1.1: (Left) Mean harm scores for 20 substances, (right) classes in Misuse of Drug
Act [5].

Harm scale determined that cocaine is the second most harmful drug and most commonly used
illicit substrates (after Cannabis) are Amphetamine-type stimulants (Amphetamine, Ecstasy) and
cocaine according to United Nations Office on Drugs and Crime (UNODC) [8]. Why such
harmful drugs are so commonly used (about 200 million people make illicit use of some type
illicit substance) [8] can be explained by their enhancing effects in the brain.

1.2

Psychostimulants

Psychostimulants are a diverse class of drugs that produce increase locomotion, cognitionenhancement, wakefulness and attention, sense of power and confidence as well as euphoria [9].

2

The strong reinforcing effect of the drugs is also responsible for its addictive effect [10]. On the
molecular level psychostimulants activate mesocorticolimbic dopaminergic system in the Central
Nervous System (CNS) [11]. Mesocortical dopaminergic pathways propagate from the Ventral
Tegmental Area (VTA) to the prefrontal cortex and are associated with psychophysiological
responses like motivation, cognitive control, and emotions [12]. Mesolimbic system originate in
the VTA and project dopaminergic neurons into the ventral striatum, which include nucleus
accumbens (NAc) and olfactory tubercle [13]. This system is particularly involved in the
development of addiction [14].

Figure 1.2: Dopaminergic pathways in CNS [15].

Stimulants increase few important neurotransmitters in the brain - dopamine, serotonin
and norepinephrine [16] [17]. The sharp increase of dopamine triggers associative (reward)
learning and conditioning [18] (two very important aspects in developing addiction). Serotonin
(5-hydroxytryptamine 5HT) is important in the sleep cycle, mood and appetite regulation [19].
Raphe nuclei are the primary site from where 5HT-neurons project to the cortex, thalamus, basal
ganglia and hippocampus [20]. Norepinephrine (NE) neurons project from the locus coeruleus
3

(LC) towards everywhere in the brain, playing an important role in the working memory
formation, enhancing attention [21] as well as in arousal and wakefulness. Psychostimulants
interfere with monoamine transporters function and elevate the extracellular concentration of
monoamines, potentiating the monoaminergic neurotransmission [22].

1.3

Monoamine transporters

Monoamine transporters are important membrane proteins that belong to the solute carrier
6(SLC6) neurotransmitter transporters gene family. The norepinephrine transporter (NET),
dopamine transporter (DAT) and serotonin transporter (SERT) are all part of this gene family.
They share similar primary sequences and all have the same overall secondary structure
consisting of 12 transmembrane domains. As mentioned above, the main function of these
transporters is to regulate neurotransmitters concentration in extracellular space by reuptake them
to the synapse [23] (Figure 1.3).

Figure 1.3: Schematic representation of monoamine transporters in neuron [23].
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Neurotransmitter uptake was first described in 1967 by Julius Axerlod [24] where he
explained how norepinephrine is reuptake into the sympathetic nerve terminal. In 1971, Iverson
[25] proposed a similar uptake process for other neurotransmitters – glycine, dopamine, GABA
and 5HT. He also pointed out that some drugs like imipramine and cocaine can inhibit uptake of
NE. Since then, many research groups had been involved in describing drugs that modulate the
reuptake of neurotransmitters. Such pharmacological modulation of neurotransmitters can
regulate neuronal activity. Indeed, neurotransmitter transporters (NTT) have become essential
therapeutic drug targets for treatment of many brain diseases like anxiety disorder, depression,
Attention Deficit Hyperactivity Disorder (ADHD), obesity, bipolar disorder and schizophrenia
[26] [27] [28] [29]. More than 30 compounds working as substrate or as non-transportable
inhibitors of monoamine transporters are currently used in clinical trials [23].
Drugs can interact with monoamine transporters in two different ways, either as a
substrates or blockers; substrates are small organic molecules or synthetic compounds that bind to
the transporter and are physically transported to the intracellular space; blockers of monoamine
transporter are not transporters inside the cell but rather bind to the transporter and inhibit its
function. Classical examples of these two groups are Amphetamine (Amph) and cocaine. The
former acts as substrate when interacting with transporters, whereas the latter acts as a blocker in
all three transporters. In the brain cocaine works as a reuptake inhibitor by blocking the reuptake
thus allowing more neurotransmitters to stay active in the synapse. Amphetamine, one the other
hand, is taken up by the transporter in exchange for neurotransmitter release into the synapse [30].
Converging evidence suggests that Amph enters the cell through monoamine transporters, and
once inside the cell, it disrupt intracellular stores of neurotransmitters. All this triggers reverse
transport of neurotransmitters through the transporters and leads to a large release of transmitter
to the cytosol [31], which is why substrates are often called releasers [32].

5

Figure 1.4: Schematic representation of dopamine, noradrenaline and 5-HT synaptic
terminals [33].

Examples of the blockers of monoamine transporters that are used therapeutically are the
following:
Tricyclic antidepressants (TCAs): Imipramine, Desipramine, Nortriptiline, Doxepin,
Amitriptyline. TCA primarily inhibits NET and SERT (14). First widely used as an antipsychotic
in a Paris hospital in 1955, few years later, it was found to be effective antidepressant [34]. It was
used as treatment for major depressive disorder (MDD), dysthymia (persistent depressive
disorder), but also social phobia, panic disorder and Post Traumatic Stress Disorder (PTSD).
Since TCAs have many other targets, they have several side effects including fatal overdose.
Fluoxetine (Prozac) first approved in 1980 [35], was one of the first Selective Serotonin
Reuptake Inhibitors (SSRI) [36]. All SSRIs have similar efficacy as TCAs [37] but a much lower
tendency to cause severe cardiovascular effects. [38] It is used to treat depression, obsessivecompulsive disorder (OCD), bulimia nervosa and panic disorder. Prozac has low physical and
psychological

dependence

liability;

accordingly,

it

is

not

a

controlled

substance.

Methylphenidate (Ritalin) is a potent blocker of DAT and NET and used for treatment of
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ADHD and narcolepsy. [39] According to the Food and Drug Administration (FDA), Ritalin is a
federally controlled substance (CII) because it can be abused or lead to dependence.
There are also monoamine transporters substrates that are used therapeutically such as
Amphetamine (Adderall) and Methamphetamine. They have higher affinities on DAT and
NET rather than SERT and are used as a treatment for ADHD, narcolepsy and obesity [40]. They
are in Schedule II controlled substance for their high potential of abuse.
Many other drugs that interact with monoamine transporters are well recognized due to
their high abuse potential. The most infamous is cocaine, which is placed in Schedule II due to its
local anesthetic usage. It has high abuse potential with loss of contact with reality, an intense
feeling of happiness, or agitation in people that abuse it. Cocaine is a powerful vasoconstrictor
and can cause vascular toxicity [41]. Other physical symptoms may include sweating, enlarged
pupils or even stroke. [42] High doses can result in very high blood pressure or body temperature.
It has high psychological and addiction liability. MDMA (Esctasy) it is a Schedule I in the USA
but in November 2016 the FDA granted permission for large-scale Phase 3 clinical trials, the final
set of human trials required before the FDA will consider a new drug useful in treatment of
PTSD. Its dependence liability is moderate to low-moderate. In the official FDA report, it is
stated, there is conflicting evidence about wherever MDMA is addictive.
At the cellular level, the adverse effect of psychostimulants includes cytotoxicity [43],
mitochondrial

dysfunction,

[44]

formation

of

highly

reactive

free

radicals

[45],

neuroinflammation and damage of the blood-brain barrier [46]. These effects of psychostimulants
contribute to long-term degradation of dopaminergic and serotonergic systems in the brain,
including attenuation in monoamine transporter activity, decrease tyrosine and tryptophan
hydroxylase function as we as deprivation of nerve terminal markers [47] [48] [49] [50].
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1.4

Drugs pharmacology on transporters

1.4.1 Abuse potential of drugs and their affinities to MAT

It is important to define which pharmacological properties of a drug define its abuse
liability. An important related question is why some drugs that interact with MAT can be used
therapeutically and others represent a high risk of abuse. It is well established that drugs that
increase dopamine level in NAc have direct positive correlation with its abuse potential, whereas
compounds that potentiate the serotonergic neurotransmission have low risk of abuse. In this
regard, the relative DAT over SERT selectivity of drugs could work as an indicator of its abuse
potential, thus, in general drugs that show higher DAT over SERT potency would probably be
abused.
Other important properties of drugs that would help to foresee its abuse potential are
whether they are substrate or blockers of the transporters. As mentioned above monoamine
transporters’ substrates potentiate neurotransmission in a more profound way than the blockers.
This is because substrates, in addition to competing the uptake of the natural substrate, they also
can induce the release of neurotransmitters. On the other hand, blockers only interfere with the
uptake, thus the increase of neurotransmitters ultimately relies only on the electrical activity of the
neuron.

1.4.2 Drug-profiling on monoamine transporters

In general, drugs that are highly selective to DAT over SERT show high abuse liability
whether or not they work as substrates or blockers on transporters; good examples are

8

methylphenidate (blocker), and amphetamine (substrate) (Figure 1.5). When compounds are not
selective, their abuse liability would depend on whether they are blockers or substrates on
transporters. Experimental evidence strongly suggests that blockers like cocaine, that are not
selective among the three transporters, show high abuse liability; whereas a non-specific substrate
like MDMA produces moderate to low abuse potential. In the case of blockers, the modest
increase of 5HT is not strong enough to counteract the effect of the increased extracellular DA,
and the abuse potential of DA will dominate. On the contrary, the strong release of 5HT
produced, a non-specific releaser (like MDMA) would counteract the abuse effect of DA. Thus,
blockers that are not selective still will show positive abuse potential, whereas substrates that are
not selective will have reduced abuse potential. In summary, drug profiling – which distinguishes
the efficacy of the drug on monoamine transporters as well as characterizing substrate or blocker
interactions – is crucial in predicting the abuse liability of the drugs.

Figure 1.5: Relative potencies in uptake studies predict abuse potential, modified from [51].
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Drug-profiling can be also useful in searching for potential candidate medications that can
be used in normalization therapy of stimulant dependence [22]. Few studies show that
amphetamine-type clinically available appetite suppressants (like phentermine, diethylpropion
and phendimetrazine) decrease cocaine and methamphetamine self-administration. It was
suggested that reduction of cocaine reinforcement could be achieved partially using serotonergic
drugs (fluoxetine, phentermine and fenfluramine) [52]. A combination of low doses of
fenfluramine with phentermine can be used in cocaine addiction [53]. Fenfluramine (5HT
releaser), that is much more potent than phentermine (DA and NE releaser and weak 5HT releaser
[54]) decreases methamphetamine self-administration [55].

1.5

Monoamine transporters drug-profiling methods

1.5.1 In vitro:

1.5.1.1 Competition assays – binding assay, uptake of radiolabeled compound

One method broadly used to test the effect of psychostimulants on monoamine
transporters is the uptake competition assay. In this method, a traceable monoamine transporter
substrate ([3H] DA, [3H] 5HT or [3H] NE) is co-applied with increasing concentrations of a test
compound. This method is used to determine the potency of compounds to inhibit transport of the
tracer. Usually these experiments are carried out either in brain synaptosomes or cells transfected
with monoamine transporters. Uptake inhibition assays cannot discriminate between test drugs
that work as substrates or blockers of the monoamine transporter.
Another method to study the monoamine transporters interaction with test drugs is the
radioligand-binding assay. This method is also a competition assay but uses high-affinity
10

radiolabeled MAT blockers as a tracer (e.g. [125I] RTI-55, [3H] CFT). The assay includes
competing the binding of these high-affinity radiolabeled ligands with different concentrations of
the test drugs. It was proposed that the comparison of potencies (Ki) of a test drug obtained using
the uptake- vs. the binding- inhibition assays could distinguish between substrates and blockers
[59]. Monoamine transporters inhibitors that are already well established in the literature, like
cocaine or fluoxetine, produce a low binding-to-uptake ratio (0.7 and 2.2 respectively), while
established substrates like Amph or DA yield high binding-to-uptake ratios (582 and 1621
respectively) [59]. The explanation for these differences can rely on pharmacological aspects of
the blockers and substrates. It is proposed that blockers and substrates bind to the different sites of
transporters that could account for the differences in the binding-to-uptake ratio [60] [61].
Unfortunately, some drugs tested later with a more direct method to classify drugs as substrates or
blockers revealed weaknesses in using binding-to-uptake ratios as a discrimination tool to identify
substrates over blockers on MATs [59].

1.5.1.2 Synaptosome

As mentioned above, just describing whether a new molecule is a ligand of monoamine
transporters without describing if it works as a substrate or blocker, would limit the prediction
that can be made about its possible biological function. Since DAT and SERT play a crucial role
in the action of abused drugs, the profile that a particular drug has in these transporters, would
essentially define its abuse liability.
One of the techniques commonly used to distinguish between substrates (or releaser) and
blockers of MAT is the synaptosome release assay. This in vitro assay measures the release of
radiolabeled [3H] MPP+ (used as more stable a dopamine surrogate) or [3H] 5-HT from
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synaptosomes [57]. Synaptosomes are nerve-ending vesicles usually isolated from the brain [62].
The name derives from its structural homogeneity and similarity to the membranes and organelles
that conform the synapse [62]. They are prepared from neuronal tissues after mild
homogenization and density gradient centrifugation (Figure 1.6) and contain all necessary
machinery for neurotransmitters uptake and release.

Figure 1.6: Schematic representation of preparation of synaptosomes. From Thermo
Fisher Scientific

“Enrich neuronal synaptic proteins while maintaining phosphoprotein

integrity” by Hai-Yan Wu, Kay Opperman and Barbara Kaboord.

For studying particular transporters, different parts of the brain are dissected. For SERT
and NET assay, whole brain minus cerebellum is used, while for DAT assay only striatum is used
[22]. Part of the brain is homogenized and incubated with 1uM reserpine that irreversibly blocks
the vesicular monoamine transporter (VMAT) and then is incubated with [3H] neurotransmitters
until a steady state is achieved. Usually [3H] 5-HT is used as the radiolabeled substrate for SERT
and [3H] MPP+ (or [3H] DA) as the radiolabeled substrate for NET and DAT [22]. After the
steady state is achieved, preloaded synaptosomes are added to a tube containing the test drug.
Substrates evoke non-exocytotic release of titrated neurotransmitters via reverse transport. The
decrease in the remaining amount of tritium (3H) will demonstrate that tested drug was a releaser
12

[22]. Blockers such as nonselective uptake inhibitor Indatraline (Figure 1.7) show a very weak
release of neurotransmitter, while transports substrate, METH display dose-dependent release on
all three transporters with high affinity on DAT and NET and low affinity on SERT [63].

Figure 1.7: Effects of the reuptake blocker Indatraline (left) and the transporter substrate
methamphetamine (right) on the release of [3H] dopamine, [3H] norepinephrine and [3H] 5-HT
in synaptosomes, taken from [22].

1.5.2 In vivo:

1.5.2.1 ICSS intracranial self stimulation

Intracranial self-stimulation (ICSS) is a method to study drug effects where rodents can
self-administer rewarding electrical stimuli. [64] Subjects are trained to press a lever to deliver
pulses via microelectrode's implanted in the brain regions such as the medial forebrain bundle
(MFB). This region of the brain allows for stimulation of the “first stage” neurons that later
project and activate “second stage” mesolimbic dopaminergic neurons in ventral tegmental area
and promotes release of DA in NAc [65].
13

Different frequencies or intensities of brain stimulations maintain different rates of lever
pressing. When the rodent is exposed to a psychostimulant, the amount of stimulation required to
get a response is smaller than when the rodents is exposed to the vehicle alone. This “facilitation”
of the ICSS is depicted as a leftward shift in the rate-frequency graph (see example of
Methamphetamine in Figure 1.8) [64]. ICSS facilitation (increase %MCR in low rates) is
interpreted as an abuse-related drug normally correlated with an exacerbated dopaminergic tone.
In addition, drugs that potentiate extracellular serotonin levels produce a depression ICSS
response at higher frequencies. This particular preclinical abuse testing method has a great
advantage of discriminating drugs increasing 5HT release, so called “abuse-limiting drugs” [66].

Figure 1.8: Effects of Methamphetamine, MDMA, Fenfluramine on full ICSS frequencyrate curves. Abscissae: frequency of electrical brain stimulation in log Hz. Ordinates: percent
maximum control reinforcement rate (%MCR), modified from [67].
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2.

Chapter two: Electrical properties of monoamine transporters and calcium channel

2.1

Monoamine transporters as channels

2.1.1 Inward current in oocytes

Monoamine transporters are proteins mainly responsible for transport cargo across the
membrane, but they contain other interesting features that characterize them as channels.
Transporters require binding and co-transport of Na+ and Cl- ions as well as the ion concentration
gradient preserved in the long term by the membrane Na+/K+ ATPase (Figure 2.1) [68] [33].

Figure 2.1: Schematic representation of monoamine transporters transport, modified
from [23].
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For each transporter we can find a net charge (stoichiometry) that is translocated during
that process generally by measuring kinetic determinants of transport rate (concentration of
substrate Km and maximal velocity Vmax) on Na+, Cl- or K+ concentrations [32]. DAT requires two
Na+ and one Cl- per 1 transported DA while NET and SERT require only one Na+ and one Cl- per
one NE or 5HT, but it is worth to mentioning that SERT during one translocation cycle
translocates one K+ out of the cell (Figure 2.2). Based on the stoichiometry of SERT, transport
appears to be electroneutral [69].

Figure 2.2: Transport of 5HT (S) in SERT coupled to Na+, Cl- and K+ co-transport [32].

It is surprising to find that oocytes expressing SERT induce an inward current when
exposed to 5HT [70]. In fact, three conductances (currents) associated with SERT have been
recognized. The first conductance (mentioned in the beginning) is induced by application of
substrate (5HT). It shows voltage rectification, and although it is activated by the substrate, it is
presumably uncoupled to the uptake mechanism.
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Figure 2.3: (Left) 5HT induced current with varied concentration of 5HT. (Right) Inhibition
of leak current by desipramine (3uM) and fluoxetine (3uM) in oocytes injected with 5HT
transporter cRNA [70].

Two other currents are transport–independent and occur in the absence of 5HT. One is the
inward current found as a consequence of a rapid change to negative potential (transient current),
and the second one is a small (size of several nanoampers) inward current called leak current; it is
constitutive to SERT expression, thus visible when transporter is inhibited by a blocker revealed
as an outward deflection in the current measurement (Figure 2.3) [70].
NET and DAT also exhibit these currents (Figure 2.4) [71] [72]. As it is mentioned before,
presumed fixed stoichiometry for NET (one NE+, one Na+, one Cl-) assumes one positive net
charge transported per cycle. The number of transporters expression vary from 106 in a HEK293
cell [71] to 1011 in Xenopus oocytes [70]. Knowing the uptake velocity for NE that was estimated
to be one NE per second, we could presume that the current evoked would be less than 0.2pA
while the patch-clamp experiment in HEK293 cells expressing hNET show currents of the order
of 100pA when cells were exposed to 30uM NE [73].
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Figure 2.4: hDAT expressing oocytes induce inward current when 10uM DA is applied and
outward during application of 10uM cocaine. No responses were elicited in control waterinjected oocyte [72].

Along with the substrate transport, transporters elicit currents in the presence of substrate
that exceeds the prediction that can be made by the fixed-coupling stoichiometry, turnover rate
and transporter density. [74] Examination of the time course of transport of 5HT in HEK293
expressing hSERT indicates that SERT functions more as a channel than a cargo-carrier. [75] A
definite experiment that describes the channel-like activity arises from direct measurements done
by Carvelli et al [74]. They described direct single-channels events that occur in Caenorhabditis
elegans DA neurons. Dopamine transporter (DAT-1) inhibitor could block DA-induced channel
activity and were absent in dat-1 KO DA neurons. All patch-clamp experiments were performed
in the presence of butaclamol and spiperone – inhibitors of DA receptor - to exclude the
possibility of currents evoked by the activation of ion channels downstream those receptors.
When the holding potential stepped from -40 to -100mV DA or AMPH, perfusion generated
significant transport-associated inward current that was abolished when Na+ was replaced with
NMDG+ (Na+ free solution) [74]. Thus, providing evidence that transporters during the transport
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cycle should adopt a conformation that constitute an ion conduction pathway that can modulate
the membrane potential in neurons from C. elegans.

2.1.2 Excitability in neurons

The functional role of the currents associated with transport of the substrate is not fully
understood. It was suggested that those currents might depolarize the membrane in dopamine
neurons since carried by Na+ ions. Ingram et al. demonstrated that DA modulates excitability in
dopaminergic neurons in the substantia nigra [76]. Extracellular DA activates D2 autoreceptors,
which are coupled to K+ channels, hyperpolarize membranes, and inhibit the electrical activity of
dopaminergic neurons [77]. However, by adding a D2 receptor antagonist, neurons experienced
rebound excitation in the presence of DA. Inhibiting a transporter, either by cocaine or a selective
DAT inhibitor in the presence of DA and D2 receptor antagonists will decrease the firing rates.
Thus, DAT is essential for substrate-induced excitation (e.g., DA or AMPH). It is proposed that
Cl- ions is the current carrier in DA neurons- a surprising and unexplained result since the inward
current carries negative charges yet elicits excitability. Therefore, another important feature
associated with DAT current is modulating excitability.
Another group showed similar effects of methamphetamine. [78] Low concentrations of
METH modulate dopamine neurotransmission by increasing dopamine-firing neurons. METH
and most amphetamine-type substrates are used to treat attention deficit disorder by enhancing
cognition. All substituted amphetamines increase DA levels in extracellular space at cell body and
axon terminal fields and lead to hyperpolarization because of autoreceptors activation. However,
low dose of METH does not generate enough D2 receptor activation to counteract the increase in
pacemaker firing rate produced by the DAT- mediated excitatory conductance and in fact
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significantly increases firing rate.
If substrate-induced currents alter excitability, they might be also associated with
activation of voltage-gated channels that are involved in excitability.

One example can be

activation of voltage-gated calcium channels. Vaarmann et al. [79] presented that dopamine can
alter cytosolic calcium. This experiment was done using neurons from hippocampal, cortical or
midbrain areas. Dopamine applied in the range 0.1 to 100uM elicited significant Ca2+ changes in
the cell body and dendrites. The calcium responses were repeated using cortical hippocampal
explant cultures where in vivo tissue properties were “well retained” to eliminate any concerns of
possible culture conditions depending properties. It was reported that changes of Ca2+ could be
increased by receptor dependent Ca2+ flow through voltage-gated calcium channels (VDCC) [80].
DA-induced Ca2+ response was receptor independent since calcium changes were not altered
while applying D1/D5 receptor antagonist. Source of the increased Ca2+ was only extracellular
because the results were replicated even when Ca2+ was depleted from ER. Moreover, the
intracellular calcium changes were completely abolished when verapamil was used, which is a
VDCC inhibitor. Interestingly, more potent VDCC blocker – nifedipine – just reduced the
amplitude of DA-induced [Ca2+]c signal but it never abolished it. Nifedipine, inhibit VGCC in the
voltage-dependent manner [81] and in the range of DA-induced depolarization probably was not
totally blocked. The activity of DAT, in particular the substrate-induced current depolarizes the
plasma membrane and this depolarization is what activates the VDCC. This provides evidence
that DA uptake through DAT depolarizes neuronal membrane and allows calcium influx by
opening VDCC.
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2.2

Voltage-gated calcium channel

2.2.1 Type of CaV and expression:

Voltage-dependent calcium channels are localized in the membrane of all excitable cells muscle, neuroendocrine cells, and neurons, and regulate the permeability to Ca2+ as a function of
membrane potential. Ca2+ channels are formed by at least 3 subunits, the main α1 subunit, and
the auxiliary β and α2δ subunits. The α1 subunit forms the ion conducting pore, whereas the
associated subunits have several functions including modulation of gating [82]. The cytosolic β
subunit is very important in stabilizing the final α1 subunit conformation and delivering it to the
cell membrane by its ability to mask an endoplasmic reticulum retention signal in the α1 subunit.
The endoplasmic retention brake is contained in the I–II loop in the α1 subunit that becomes
masked when the β subunit binds [83]. Therefore, the β subunit functions initially to regulate the
current density by controlling the amount of α1 subunit expressed at the cell membrane. In
addition to this trafficking role, the β subunit plays an important function in regulating the
activation and inactivation kinetics. CaV inactivates in voltage- and Ca2+ -dependent manner [84]
and this process can be modulated by β by generally shifting voltage-dependence of inactivation
to more negative voltages, usually about 10-20mV. The most profound increase in channel
probability produce β2A [85] while β2e decelerate inactivation [84].
Voltage-gated Ca2+ channels might be defined by having different α1 subunit as - CaV1,
CaV2, and CaV3. The first group, CaV1 are called L-type calcium channels. The currents through
those channels are distinguished by large single channel conductance, slow voltage-dependent
inactivation and high voltage activation with one exception, CaV1.3 L-type Ca2+ channel that is
not high voltage activated [86]. CaV3, also known as T-type (transient opening) is characterized
by low voltage activation, rapid inactivated, slow deactivated and small channel conductance
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[87]. CaV2 family of Ca2+ channel has more negative and faster voltage dependence but more
positive and slower than T-type. Neuronal presynaptic Ca2+ channels, P/Q, N and R –type, require
strong depolarization and are coupled to neurotransmitters release [88].
Dopaminergic neurons that demonstrate two predominant activity patterns termed tonic
and phasic [22]. It was shown that in mouse VTA, firing activity is regulated by L-type Ca2+
channel, in particular CaV1.2 and CaV1.3 [23]. CaV1.3 activation is necessary for basal singlespike firing, while burst firing is supported by activation of both subtypes. Since CaV channels
play important roles in neuronal excitation, some studies pointed out the possibility that substrateinduced monoamine transporter currents can regulate membrane excitability through activation of
CaV channels.
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3.

Chapter three: Hypothesis and Aims:

3.1

HYPOTHESIS 1: Monoamine transporters substrates indirectly activates voltage-

gated calcium channels
3.1.1 AIM1: Expression of monoamine transporters and calcium channels in heterologous
expression system
3.1.2 AIM2: Identification of the substrate-induced current at monoamine transporter
3.1.3 AIM3: Opening of voltage-gated calcium channels due to depolarization induced by
monoamine transporter activation
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3.2

HYPOTHESIS 2: Electrical coupling between calcium channels and monoamine

transports can discriminate substrates and blockers of the transporters
3.2.1 AIM1: Developing protocols for identification of substrates and blockers
3.2.2 AIM2: Characterization of calcium sensors
3.2.3 AIM3: Optimization of calcium channels subunits in hDAT and hSERT
3.2.4 AIM4: FlexStation as calcium mobilization assay technique in first approach for
High Throughput Screening (HTS)
3.2.4.1 Optimization: testing sensitivity of known drugs in FlexStation
3.2.4.2 Testing set of newly synthesized drugs
3.2.4.3 Secondary post screening: detailed analysis using epifluorescence microscopy
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4.

Chapter four: materials and methods

4.1

Culture of HEK293

HEK293 cells were prepared in Dulbecco’s modified Eagle’s medium

(DMEM)

supplemented with 10% fetal bovine serum (FBS), penicillin (100units/ml) and streptomycin
(100g/ml) and were incubated at 37oC to reach 80% confluence. Subsequent splitting was done
using PBS/Trypsin solution. DMEM with FBS was used to stop trypsin activity. 10% of cells
were plated in new culture dish for subsequent grow.

4.2

Generation of Flp-In Trex cells and permanently expression of MOT

To generate inducible cell lines that permanently express one of the monoamine
transporter of interest (hDAT or hSERT) cells undergo Flp-InTMT-RExTM293 (Flp) (Invitrogen)
expression system. Flp-InTM T-RExTM cell lines are HEK cells that contain FRT recombination
site and Tet repressor gene. To generate cells expressing hSERT, Flp cells were co-transfected
with pcDNA5/hSERT-IRES-DsRED/FRT/TP (that was previously created by subcloning hSERTIRES-DsRED DNA fragment with pcDNA5/FRT/TP vector) and plasmid encoding the Flp
recombines pOG44 plasmid. Clones that have inserted a single copy of the gene of interest into
the recombination site acquire a hygromycin resistance. hDAT expressing cells undergo very
similar process, the only difference is hDAT cDNA ( accession number : NM_001044) do not
have IRES_DsRED sequence.
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4.3

Experimental solutions

Imagine solution IS (all values in mM): 130 NaCl, 4 KCl, 2 CaCl2, 1 Mg Cl2, 10 Hepes, 10
glucose, with pH adjusted to 7.4.
High K+ solution: 134 KCl, 2 CaCl2, 1 Mg Cl2, 10 Hepes, 10 glucose, with pH adjusted to 7.4.
Internal solution (for patch clamp): 135 mM CsCl, 10 mM Cs2-EGTA, 1 mM CaCl2,4 mM
MgCl2, and 10 mM Hepes, pH 7.4 with CsOH.
External solution (for patch clamp): 155 mM tetraethylammonium (TEA)-Cl, 5 mM CaCl2and 10
mM Hepes, pH 7.4, with TEA-OH.

4.4

Transient transfection

For epifluorescence experiment Fln-hMAT were cultured in 96 well imaging plate at
about 30% confluence at day one. On second day cells, undergo transfection using Fugene 6
(Promega) as transfection reagent. The CaV2.2 ( α1B), CaV1.3 (α1D), β3 and α2δ expression
plasmids were obtained from Addgene (cat# 26570, 26571, 26574 and 26575, respectively) and
were kindly provided by Dr. Diane Lipscombe (Department of Neuroscience, Brown University,
Providence, Rhode Island, USA). The CaV1.2 (α1C accession number: NM 001136522) was
kindly provided by Dr. Manfred Grabner (Department of Medical Genetics, Molecular, and
Clinical Pharmacology, Innsbruck Medical University, Innsbruck, Austria). Cells were transfected
with calcium channels subunits in ratio α1:β3:α2δ:EGFP=1:1:1:0.2, where EGPF expression vector
was a transfection marker. Lipofectamine was used in the cells co-transfecting hSERT-IRESDsRED with calcium channels.
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4.5

Intracellular Ca2+ determination

Intracellular calcium was measured using Ca2+ sensitive dyes Fluo-4AM or Fura-2AM
(Life Technologies). Dyes vials were dissolved in DMSO pluronic F-127 20% and stored at -20C
until used.

Prior to experiment dyes/DMSO were diluted in imagine solution IS for final

concentration 5.5uM. 50ul of either dye were loaded into the cells and placed into 37°C for 12
min (Fluo-4AM) or for 25 min (Fura-2). After incubation time dye solution was replaced with IS
and cells were kept at RT for about 25 min. Visualization of calcium signal was done using
epifluorescence microscope following the method described previously. [89] Measurements were
done under constant perfusion at RT or at 35°C using an excitation wavelength of 490/10nm, a
dichroic mirror and an emission wavelength of 535/50nm for Fluo-4. The Fura-2 signals were
acquired by switching the excitation wavelength between 340/10nm and 380/10nm at 6Hz and the
emission wavelength was 510/40nm. Transfected cells were identified by visualization of DsRed
(excitation 510/10nm, emission 620/60nm) or EGFP (excitation 490/10nm, emission 535/50nm).
The reported values are the fluorescence values divided by the basal level of each cell and
reported as ∆F/Fo forFluo-4 and ∆F(340/380)/Fo for Fura-2. All signals were background subtracted.
The Ca2+ signal was acquired at 50 or 100 Hz as indicated in the figure legends for Fluo-4 or 3 Hz
(ratio image) for Fura-2.
The dose-response relationships for Ca2+ and [3H]-5HT uptake experiments were fit by the
equation: (1)

Y (X) =

Ymax
[1+10 exp({log EC50 ! log X}* n)]

(1)

where X is the concentration of 5HT or S(+)MDMA applied, Y(X) is the response measured,
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Ymax is the maximal response, EC50 is the concentration that produces half-maximal response,
and n is the Hill slope parameter.

4.5.1 APP+ uptake assay

To monitor hSERT uptake we used previously described APP+ (4-(4-(Dimethylamino)
phenyl)-1-methylpyridinium). APP+ is fluorescent substrate transported by hSERT used to
monitor hSERT activity by fluorescence microscopy as previously described [90]. It does not
exhibit fluorescence while outside cells, nor during interaction with transporter. APP+ can
fluoresce only after changing confirmation from “twisted” intermolecular charge transfer stateforming compound (TICT) to co-planar confirmation (ref). This co-planar confirmation is
energetically more favorable when APP+ binds to intracellular molecules such as proteins, DNA
or RNA. When APP+ is transported, it diffuses in the cytosol and later on is accumulated in
mitochondria and nuclei. Cells grown on imaging plates were placed on the stage of the
fluorescence microscope describe above. The wavelengths used to detect the APP+ signal were
460/10 nm for excitation and 535/50 nm for emission.

4.6

Radiolabeled uptake studies

Flp-In cells expressing hSERT were counted and 2 × 106 cells were exposed to different
concentrations of 5HT where 3% of a given concentration consisted of [3H]-5HT. The 5HT
uptake was carried out for 10 min at 37◦C in IS (see composition above). Non-specific uptake was
measured adding 5µM fluoxetine to the radioactive mixture. Then the cells were centrifuged,
washed once with cold 1X PBS, centrifuged again, cell pellets were resuspended in Ecoscint H
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(National Diagnostics, Atlanta, GA, USA), and the radioactivity counted using a liquid
scintillation counter. The mean ± S.E.M. of 5 independent experiments done in duplicates are
reported.

4.7

Whole cell patch clamp

Macroscopic Ca2+ currents (ICa) were measured as previously described [91]. External
solution and the patch pipette internal solution compositions are described above. The whole-cell
patch-clamp parameters of the recordings were: cell capacitance = 27 ± 3 pF, access resistance =
5.5 ± 0.5 MΩ, τ= 153 ± 26 µs (n = 14). The effective series resistance was compensated and
corrected by 80% using the Axopatch circuit. In these conditions, the remaining voltage error is
<1.5 mV. The leak current was subtracted using a −P/6 protocol before each sweep. The pipettes
were fire polished, Sylgard coated and had a resistance of ∼2.5 MΩ when filled with the internal
solution. The liquid-junction potential was not corrected. The recorded signals were acquired at
10 kHz and filtered at 5 kHz. The voltage dependence of the ICa was fit to the following equation:

I Ca =

Gmax (V !Vr )
1+ exp((V1/2 !V ) / k)

(2)

where Gmax is the maximal conductance, V is the test potential,V1/2 is the potential at which G =
1/2 Gmax, k represents a slope parameter and Vr is the reversal potential.
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4.8

Flexstation calcium mobilization assay

Cells that permanently express hDAT or hSERT were co-transfected with CaV1.2
(auxiliary subunits were used when indicated on the graphs) and GCamp6s coding plasmids, and
plated in a 96 well-imaging plates. After 3 days of transfection, growing media was replaced with
50ul of IS and cells settled for 25min.
Time-lapse of the fluorescent signal was acquired in a Flex Station 3 that allows for simultaneous
reading of 8 wells (one column in 96 well-plate). Data were acquired using SoftMAx Pro
software with following settings: fluorescence read mode with excitation and emission
wavelength: 488nm and 525nm; PMT sensitivity: high; run time: 180sec with interval length
1.69sec; total number of reads 107. Maximal pipette height is 50ul with a total volume of 80ul
and rate of injection 3 (~47ul/sec). Time point (which is the time after drug was injected) was
30sec.

4.9

Statistics and data analysis

All data are presented as mean ± S.E.M. unless indicated in the figure legend. Comparisons were
made by unpaired, two-tailed t-test, with p < 0.05 considered significant.

30

5.

Chapter five- results: Monoamine substrate indirectly activate voltage gated calcium

channels

5.1

Expression of hSERT in HEK293 cells

Expression of hSERT after transfecting HEK293 cells with hSERT-IRES-DsRed plasmid
was evaluated by immunostaining and epifluorescence microscopy. The hSERT signal is shown
in green and the DAPI nuclear staining is shown in blue (Figure 5.1) Cells not transfected with
hSERT did not show green immunofluorescence as is shown in Figure 5.1B (Scale bar = 100 µm).
Using confocal microscopy we could depict hSERT membrane localization in transfected cells
subjected to immunostaining (Figure 5.1C) (Scale bar = 10 µm). Further evidence of hSERT
expression is the detection of a specific band of ~80 kDa by Western blot analysis in samples
transfected with hSERT-IRES-DsRed plasmid (Figure 5.1D). Cells transfected with the hSERTIRES-DsRed plasmid were exposed to APP+ for 1 min and APP+ uptake was evaluated by live
fluorescence microscopy. To demonstrate that hSERT expressed by the cells is a functional
transporter we subjected the cells to fluorescence APP+ substrate, the APP+ signal is shown in
green in Figure 5.1E. Merging of the green (APP+) and red (DsRed) channels show only cells
expressing hSERT uptake APP+ (Figure 5.1F). Other cells (not transfected) depicted in DIC
image (Figure 5.1G) do not uptake APP+. Representative traces of the kinetics of APP+ uptake is
shown in Figure 5.1H. Time-lapse experiments show that APP+ uptake is completely abolished by
fluoxetine (selective hSERT inhibitor) in DsRed positive cells (Figure 5.1I).

31

Figure 5.1: Expression of hSERT in HEK293 cells. Cells were transfected with the hSERTIRES-DsRed plasmid. (A) hSERT expression was evaluated by immune-staining and
epifluorescence microscopy. The hSERT signal is shown in green and the DAPI nuclear
staining is shown in blue. (B) Immunofluorescence of non-transfected cells. Scale bar = 100µm.
(C) Confocal image showing the membrane localization of hSERT in transfected cells subjected
to immunostaining. Scale bar = 10 µm. (D) The lower image is a western blot showing the
expression of hSERT only in samples from cells transfected with hSERT-IRES-DsRed plasmid
(+) but not from cells transfected with the empty vector (-). The upper image shows the total
protein content as a loading control for the same samples evaluated by SDS-PAGE and
Coomassie blue staining (standards in kDa). (E) Cells transfected with the hSERT-IRES-DsRed
plasmid were exposed to APP+ (fluorescent hSERT substrate [90]) for 1 min and APP+ uptake
was evaluated by live fluorescence microscopy. The APP+ signal is shown in green. (F)
Merging of the green (APP+) and red (DsRed) channel. (G) Merging of the green channel
(APP+) and the DIC image. (H) Representative traces of the kinetics of APP+ uptake for several
minutes. The black trace shows the control condition and the grey trace shows the effect of
fluoxetine (FLX). (I) The first derivative (rate) of the APP+ uptake plotted as a function of time.
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5.2

The intracellular Na+ concentration induced by SERT substrates

Since 5HT induces inward current that consist partly of Na+ ions [92] we wanted to study
intracellular Na+ in hSERT expressing cells. Cells exposed to SERT substrates (5HT or
S(+)MDMA) increase intracellular Na+ concentration which is shown in Figure 5.2 A and B.
Although both hSERT substrates showed potencies in a similar range, S(+)MDMA is more
efficacious than 5HT at elevating internal Na+. Raising the temperature from 23ºC to 35ºC
significantly increased the Na+ permeability induced by both substrates (Figure 5.2 C). Using
whole-cell voltage clamp ionic current was measured at a holding potential of -60 mV.
Transfected cells were exposed to 10 µM S(+)MDMA for 50 s and after a 2 min wash the cells
were exposed to 10 µM 5HT also for 50 s and then washed again for 1 min. The experiments were
done under constant perfusion at 35°C. Ionic currents induced by 5HT (I5HT) or S(+)MDMA
(IMDMA) showed identical initial peaks followed by a slow decay (Figure 5.2 D). It is possible that
some blocking mechanism 5HT induced some blocking mechanism, which inhibit in part the
current after longer exposure.
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Figure 5.2: S(+)MDMA and 5HT show increase in intracellular Na+ in hSERT expressing
cells. HEK293 cells transfected with the hSERT-IRES-DsRed plasmid were loaded with the
permeable Na+ sensitive dye Asante NaTRIUM Green-2 AM. (A) Intracellular Na+ increase
induced by 5HT (black trace) or S(+)MDMA (grey trace), both 10 µM and at room temperature
(23 °C) or (B) at 35°C. (C) The intensity of the Na+ signal after 50 s exposure to S(+)MDMA
(grey bars) or 5HT (black bars) either at room temperature (RT) or at 35°C. (D) Ionic currents
measured by whole-cell voltage-clamp technique at a holding potential of -60 mV. Transfected
cells were exposed to 10 µM S(+)MDMA for 50 s and after a 2 min wash the cells were
exposed to 10 µM 5HT also for 50 s and then washed again for 1 min. The experiments were
done under constant perfusion at 35°C. (E) Normalized current intensities at the peak or after
50 s exposure (I50s) to S(+)MDMA (grey bars) or 5HT (black bars).
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5.3

Voltage-dependence of CaV1.3- and CaV2.2- mediated Ca2+ currents.
To test the hypothesis that either I5HT- or IMDMA- induced depolarization can activate LVA

Ca2+ channels, the CaV1.3 (LVA) - or as a control, CaV2.2 (HVA) Ca2+ channels - were coexpressed with hSERT in HEK293T cells. As shown by others [93] and confirmed here, the Ca2+
current (ICa) of CaV1.3 has a 34 mV left shift in its voltage dependence curve compared to the ICa
of CaV2.2. Therefore, the activation threshold of ICa is ~-35 mV and ~0 mV for CaV1.3 and
CaV2.2, respectively (Figure 5.3).
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Figure 5.3: Voltage-dependence of CaV1.3- and CaV2.2- mediated Ca2+ currents.
HEK293T cells were co-transfected with hSERT-IRES-DsRed, β3, α2δ1 and alternatively
CaV1.3 (closed black circles) or CaV2.2 (open gray circles) plasmids. The experiments were
done under constant perfusion at 35°C. The currents were evoked by a trend of pulses starting
at a holding potential of -60 mV in steps of 10 mV. Representative family of responses for
CaV1.3 and CaV2.2 are shown in A and B, respectively. C, The current-voltage dependence of
the peak current densities was fit according to Eq.1 (Materials and Methods) for CaV1.3 (black
trace) and CaV2.2 (grey trace). The data are expressed as mean ± SEM. The fitting parameters
are the following: Gmax, 2,394 ± 312 and 2,336 ± 251 (pS/pF); V1/2, -17 ± 1.5 and 16*** ± 1.0
(mV); k, 3.9 ± 0.43 and 3.1 ± 0.33 (mV) for CaV1.3 (n = 7) and CaV2.2 (n = 5) respectively. ***
= p < 0.0001, t-test.

5.4

The depolarization induced by hSERT activation is electrically coupled to CaV1.3

opening

To study the electrical coupling between hSERT and these Ca2+ channels, the cotransfected cells were subjected to intracellular Ca2+ determination by fluorescence microscopy as
described in Materials and Methods. When hSERT was expressed without either CaV channel, the
cells did not respond to hSERT substrates or to high K+-depolarization (Figure 5.4 A). In contrast,
5HT and S(+)MDMA evoked fast Ca2+ transients when CaV1.3 (but not CaV2.2) was co-expressed
with hSERT. Nevertheless, high K+ depolarization evoked Ca2+ transients when either Ca2+
channel was expressed (Figure 5.4 B and C), demonstrating that hSERT-mediated depolarization
activates CaV1.3 but not CaV2.2. Finally, cells transfected with CaV1.3 in the absence of hSERT
only have a positive response to high K+ depolarization, whereas S(+)MDMA or 5HT show no
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effect (Figure 5.4 D).

Figure 5.4: HEK293T cells were loaded with the permeable Ca2+ sensitive dye Fluo-4AM and
the intracellular Ca2+ concentration was measured by fluorescence microscopy at an acquisition
rate of 50 Hz. The tested ells were transfected with the following plasmids: (A) hSERT-IRESDsRed (without CaV channel); (B) α1B (CaV2.2) and hSERT-IRES-DsRed; (C) α1D (CaV1.3)
and hSERT--IRES- DsRed; (D) α1D (CaV1.3) and DsRed (without transporter). (A-D) As
indicated in each trace, the cells were exposed to 10 µM S(+)MDMA (light grey box) or 10 µM
5HT (dark grey box) for 5 s. After wash the cells were exposed to 200 nM valinomycin (V, white
box) for 2s to increase the K+ permeability and were immediately exposed to 130 mM K+
solution for 5s (K+, black box) to depolarize the cells toward positive potentials, then after wash
the cells were exposed to 3µM 4Br-A23187 - Ca2+ ionophore. The traces shown are mean ±
s.e.m. of n ≥ 20 cells.
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5.5

5HT shows higher potency activating hSERT/CaV1.3-mediated Ca2+ signals than

inducing its transport.
The over-expression of hSERT in transient transfection experiments would lead to nonphysiological levels of depolarization upon challenging the cells to hSERT substrates. To address
this concern, a stable cell line expressing the hSERT–IRES–DsRED construct was generated
using the Flp-InTMT-RexTM expression system as described in Materials and Methods. Since
these cells are restricted to a single copy of the gene of interest, the expression level of the
inserted gene is lower than in transient tranfection experiments. Using the APP+ assay, the Flp-In
cells showed 60% less hSERT maximal activity than HEK cells subjected to transient transfection
with the hSERT–IRES–DsRED plasmid, both the transient transfection of HEK cells and the
induction of Flp-In cells were carried out 3days prior to the experiment (Figure 5.5 A). Similarly,
the DsRed signal was reduced 93% in Flp-In cells (Figure 5.5 A). Although hSERT activity is
reduced in Flp-In cells, when they were transfected with CaV1.3, 5HT induced Ca2+ signals in a
dose-dependent manner (Figure 5.5 B) whereas un-transfected Flp-In cells (no Ca2+ channel but
expressing SERT) are refractory to 5HT treatment (not shown). Interestingly, dose-response
experiments for [3H]-5HT uptake done in Flp-In cells showed an EC50 of 1.68 ± 0.38 µM (n = 5,
Figure 5.5 C), whereas the EC50 for the Ca2+ signal induced by 5HT in these cells was 0.90 ± 0.08
µM (n > 57, Figure 5.5 C) (p < 0.01, t-test). The comparable potency of both actions of 5HT, as a
substrate of hSERT, and driving hSERT-mediated depolarization toward CaV1.3 activation,
suggests that the coupling between hSERT-mediated depolarization and CaV channel opening is
significant in the physiological range of 5HT concentration.
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Figure 5.5: The electrical coupling between hSERT and CaV1.3 take place in the
physiological concentration range of 5HT. (A) Flp-InTMT-RexTMcells (Flp-In, open circles)
expressing the hSERT-IRES-DsRed constructs was generated as described in Material and
methods, and HEK293 cells (closed circles) were subjected to transient transfection using the
hSERT-IRES-DsRed plasmid. To compare the activity of hSERT among cell types, the maximal
rate of APP+ uptake was measured computing the maximum of the first derivative of APP+ signal
as function of time. In addition, the DsRed signal was measured for each cell. The maximal rate
of APP+ uptake (y axis) and DsRED fluorescence (x axis) is plotted for each individual cell (note
that the axis are in logarithmic scale) and the values shown are the mean ± _standard deviation.
The hSERT activity was 44.8*** ± _15.4 (a.u./s), and110.4 ± _55.0 (a.u./s) for Flp-In cells (n =
202) and HEK293 cells (n = 107), respectively (***p < 0.0001, t-test). The DsRed signal was
119*** ± _60 (a.u.) and 1821 ± 1310, for Flp-In cells (n = 202) and HEK293 cells (n = 107),
respectively (***p < 0.0001, t-test). (B) Flp-In cells were transiently transfected with CaV1.3 as
described in Material and methods, the transfected cells were identified by the EGFP fluorescence
and the Ca2+ signal was determined using Fura-2AM. Measurements were done under constant
perfusion at 35◦C and the acquisition frequency was 3 Hz. The cells were exposed to a variable
concentration of 5HT followed by 30 µM 5HT to record the maximal response. The traces shown
are mean ± _S.E.M. of n ≥ 57 cells for each condition. (C) The dose–response experiments shown
in B were fit to Eq. (2) (Materials and methods) and yield the following fitting parameters for the
5HT-dependent Ca2+ signal: maximal response = 0.519 ± 0.013 ([F340/380/Fo]), EC50= 0.90 ± 0.08
(µM) and Hill slope = 1.15 ± 0.12 (n > 57). The dose response of [3H]-5HT uptake in Flp-In cells
was fit to Eq. (2) (Material and methods) and yield the following parameters. Maximal response =
55,155 ± _5512 (cpm), EC50= 1.68 ± 0.38** (µM) and Hill slope = 1.55 ± 0.43 (n = 5, **p <
0.01 vs. EC50 of Ca2+ experiments, t-test). The fitted curves of the Ca2+ signal and [3H]-5HT
uptake experiments were normalized and superimposed for better comparison.
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6.

Chapter six- results: Electrical coupling between calcium channels and monoamine

transports can discriminate substrates and blockers of the transporters

6.1

A. Developing calcium protocol for substrates and blockers

Cells expressing hDAT were transfected 3 days before the experiment with CaV (all
subunits). Calcium visualization was done using epifluorescence microscopy after loading cells
with Fura 2 (for details see Materials and Methods). Using this Ca2+ assay, it is possible to detect
substrates or blockers of monoamine transporters. Examples of substrate and blocker protocols
are shown in Figure 6.1 where hDAT-expressing cells undergo exposure to the control (hDAT
cells are exposed to 10µM DA) for 5 second (first peak signal) under constant perfusion. The
second peak represents perfusion of the cells with different concentrations of the studied substrate
(in our example N-Methyl 4-MA) for 5 sec [94]. Both the control and the studied drug were
washed with IS for 30 second (Figure 6.1 A). Since blockers do not produce Ca2+ signal,
concentration-dependence signal is acquire by blocking the Ca2+ signal evoked by the control
compound DA for hDAT cells or 5HT for hSERT not shown (Figure 6.1 B).
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Figure 6.1. Identification of substrate (A) or blocker (B) of monoamine transporters using
Ca2+ imaging. Cells co-expressing hDAT and CaV1.2 show Ca2+ signals when exposed to
10uM DA (first Ca2+ peak) and concentration-dependent increase of Ca2+ signal when exposed
to substrate, N-Methyl 4-MA (second Ca2+ peak, top figure). For blockers, second Ca2+ peak
represent concentration-dependent blockade using N-Ethyl 4-MA of the Ca2+ signal produced
by control (5µM DA).

Calcium signal induced after application of the substrate is an indirect measurement of
substrate-induced current of monoamine transporter. To directly test this current, oocytes were
transfected with hDAT cRNA; recordings were done at room temperature using TEVC under
constant perfusion. Two drugs tested previously in HEK cells (Figure 6.1) were used, N-Methyl
4-MA and N-Ethyl 4-MA, which are shown in Figure 6.2. 10µM N-Methyl 4-MA induces 30nA
inward current that is correlated with the data in HEK293 cells where 10uM N-Methyl 4-MA
induces the opening of the calcium channel and increase in intracellular calcium. N-Ethyl 4-MA,
on the other hand, induces outward current at -60mV, which indicates blockage of endogenous
leak current hDAT.
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Figure 6.2. Effect of N-Methyl and N-Ethyl 4-MA on membrane currents in oocytes
injected with hDAT cRNA. Modified from [94].

6.2

Finding the least amount of subunits required to have functional calcium channels

As was mentioned earlier (see introduction), beta subunit is important in the expression of
the calcium channel. To find the least amount of subunits required for functional calcium channel
and electrical coupling with transporters hDAT cells were transfected with varied amounts of
subunits. Cells were subsequently transfected with α1C + β3, α1C + α2δ, or α1C alone. The calcium
signals shown in Figure 6.3 represent response to 10µM S(+)Amph and 135mM K+. Cells
expressing only pore domain α1C show signals very similar to cells expressing additional subunits.
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Figure 6.3: Ca2+ signals in hDAT-expressing cells transfected with CaV1.2 (α1C) and
auxiliary subunits.

Dose-response experiments for S(+)Amph were conducted in cells transfected with the α1C alone
or α1C, β, α2δ (Figure 6.4). Cells co-expressing hDAT and CaV1.2 with all auxiliary subunits
produce Ca2+ signals with EC50, almost identical to cells expressing only α1C subunit (see also
table), EC50 ± SEM of n ≥100.
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Figure 6.4: Ca2+ signals in hDAT-expressing cells transfected with CaV1.2

and varied

auxiliary subunits. (A) Normalized Ca2+ signals in hDAT-expressing cells transfected with
CaV1.2 and all auxiliary subunits (α1C, β, α2δ) using Fura-2. (B) Normalized Ca2+ signals in
hDAT-expressing cells transfected with CaV1.2 α1C (no auxiliary subunits). (C) Dose response of
S(+)Amph normalized to control (10µM DA). EC50=0.12µM for cells transfected with CaV1.2
and all auxiliary subunits (α1C, β, α2δ) while EC50=0.19µM with cells transfected with α1C (no
auxiliary subunits).
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Ca2+ signals acquired in hSERT expressing cells are shown in Figure 6.5. Dose-response
experiments for N-Methyl 4MA were conducted in cells transfected with all subunits (α1C, β, α2δ),
α1C alone, and α1C and β (Figure 6.4 B, C, E). Cells expressing hSERT should be transfected with
at least the β auxiliary subunit to evoke calcium signals that are similar in size to signals evoked
by cells expressing all auxiliary subunits (Figure 6.5 E).
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Figure 6.5: Normalized Ca2+ signals in hSERT-expressing cells transfected with CaV1.2 and
varied auxiliary subunits (α1C, β, α2δ) using Fura-2. (A) Cells transfected with CaV1.2 and all
subunits α1C, β3, α2δ. (B) Cells transfected with CaV1.2 α1C (no auxiliary subunits). (C) Cells
transfected with CaV1.2: α1C and β3. (B) Dose response of N-Methyl 4MA normalized to control
(10µM 5HT) in cells expressing all auxiliary subunits (α1C, β3, α2δ) (red) and α1C and β (black).
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6.3

Determination of dynamic rage, sensitivity and kinetics of calcium sensors (Fluo4

and GCaMP’s)

6.3.1 Molecular characteristics of genetically encoded Ca2+ sensors

GCaMPs are a new class of genetically encoded indicators of intracellular calcium. These
high-sensitive proteins have been widely used in determining rapid neuronal calcium dynamics
[95]. They consist of circular permuted green fluorescence protein (cpEGFP) that is attached to
calcium-binding calmodulin (CaM) and CaM-interacting M13 a peptide sequence from myosin
light chain kinase. In a normal condition, (low Ca2+ state) (Figure 6.6) chromophore is in a poor
fluorescent and absorbance state due to the water pathway that enables protonation of the
chromophore. In the presence of Ca2+, CaM undergoes hinge motion that allows binding of M13,
thus rearranging the structure in a way that removes the solvent pathway, causing rapid reprotonation of the chromophore and fluorescence [96].

Figure 6.6: Crystal structure of Ca2+ -free (left) and Ca2+-saturated (right) GCaMP. Picture
taken from [97]
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Since the first introduction, GCaMP underwent many optimizations using mutagenesis. Mutations
usually took place on the interface between cpGFP and CaM and yielded different sensitivity
variants with more sensitive sensors having slower kinetics. Here, two ultrasensitive GCaMP6
sensors - GCaMP6s with slow kinetics and GCaMP6f that was considered the fastest genetically
encoded calcium indicators in neurons were tested [95]. We also wanted to test GCaMP-CAAX
membrane tethered version of GCaMP6s since we would expect that membrane-targeted sensor
should have higher sensitivity due to its closest proximity to calcium channels.

6.3.2 Efficiency of the calcium dyes

Three GCaMP including GCaMP6s, GCaMP6f, GCaMP6s-CAAX were tested. They were
compared to Fluo-4, well-established Ca2+ dye used to measure intracellular calcium (Figure 6.6).
All experiments were done in the same conditions. To test Fluo-4, cells expressing hDAT were
transfected with CaV1.2 α1C and before the experiment 50µl of Fluo-4 were added to the cells and
incubated for 15min at 37°C. After that the solution with Fluo-4 was exchanged for IS and cells
settled for 25min. The experiment was then performed. Since GCaMPs are genetically encoded,
they were co-transfected with α1C in hDAT-expressing cells. Before the experiments, IS was
exchanged with DMEM media and cells settled for 25minues. Cells underwent exposure to 10µM
DA, 5 µM Amph and 134mM K+. GCamP6s is the brightest among the Ca2+ sensors, yielding a
very large fluorescent signal ~5 fold over the baseline in average (Figure 6.7).
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Fig. 6.7 Comparison of Ca2+ signals using single wavelength Ca2+ sensors (A) ∆F
Fluorescence, (B) raw data. Either 10 µM dopamine or 5 µM S(+)Amphetamine induces Ca2+
signals in hDAT cells co-expressing CaV1.2 (no auxiliary subunits were included in the
transfection mix).

Since GCaMP6’s sensor yields robust Ca2+ signals after exposure to monoamine
substrates and can be used in drug-profiling purposes we wanted to analyze how monoamine
transporters affinities of drugs vary using this biosensor. To achieve that, we examined drugs
previously tested using Fura-2. hDAT-expressing cells transfected with only pore α1C subunit
underwent exposure to different concentrations of Amph, yielding EC50=0.31±0.02 µM (Figure
6.8). hSERT-expressing cells were transfected with α1C and β subunits yielding EC50=0.44±0.03
µM.
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Figure 6.8: Ca2+ signals using GCamp6s. (A) Ca2+ signals in hDAT-expressing cells transfected
with CaV and α1C. (B) Dose response curve with EC50=0.31±0.02 µM (C) Ca2+ signals in
hSERT-expressing cells transfected with CaV α1C and β.

(D) Dose response curve with

EC50=0.44±0.03 µM.

To induce calcium signals in hSERT-expressing cells using Fura-2, we had to transfect
cells with α1C and β auxiliary subunit (Figure 6.4). Interestingly, hSERT cells expressing only α1C
and GCaMP6 induced calcium signals when challenged with N-Methyl 4MA, although with
lower potency (EC50=1.1±0.1µM) (Figure 6.9), than hSERT expressing α1C and β (EC50=0.4µM).
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Figure 6.9: Ca2+ signals using GCamp6s in hSERT expressing cells transfected with α1C. (A)
Ca2+ signals in hSERT-expressing cells transfected with CaV and α1C. (B) Dose response curve
with EC50=1.1±0.1 µM.
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Figure 6.10: EC50 of Amph/4-Methyl 4-MA in Ca2+ signals in hDAT/hSERT -expressing cells
transfected with varied auxiliary subunits. All data are presented in µM.
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6.4

Flex Station as calcium mobilization assay technique in first approach for HTS

6.4.1 Ca2+ signals determined using either Fluo4 or GCamP6s in Flex Station plate reader.

To minimize the time of drug-profiling using Flex Station as Ca2+ mobilization assay, in
which 96-well imaging plates were transfected either with hDAT or with hSERT-expressing cells.
Cells were either loaded with Fluo-4 or transfected with calcium sensors GCaMP6s as indicated.
The application of S(+)Amph (red traces) produced robust increase in fluorescence. Cells
expressing GCaMP6s generated a much higher fluorescence signal when exposed to this substrate
compared to cells loaded with Fluo 4 (Figure 6.11). GCaMP6s generated robust increase in
fluorescence in hSERT-expressing cells (Figure 6.12) when cells were exposed to S(+)MDMA
(green trace). Signal was completely blocked during application of hSERT blocker Fluoxetine
(gray trace).
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Figure 6.11: Substrates and blockers of the dopamine transporter are identified using the
Flex Station 3 plate reader and the Ca2+ sensors Fluo-4AM (left) or GCaMP6s (right) Cells
that permanently express hDAT were co-transfected with CaV1.2 (no auxiliary subunits) and
GCamp6s coding plasmids, and were plated in a 96 well-imaging plates. Time-lapse of the
fluorescent signal was acquired in a Flex Station 3; the injection of drugs in each well is indicated
by the arrow. Control responses include IS (control imaging solution, black traces), 4Br-A23187
(Ca2+ ionophore, green traces), 90mM K+ solutions (blue traces). The signal induced by the
hDAT substrate S(+)AMPH (red trace) was blocked by pre-incubating the cells with MDPV
(hDAT blocker, gray trace). Traces are plotted as mean ± SEM of n=6.
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Figure 6.12: Substrates and blockers of the serotonin transporter are identified using Flex
Station 3 plate reader. Cells that permanently express hSERT were co-transfected with CaV1.2
(α1C and β) and GCamp6s coding plasmids, and were plated in a 96 well-imaging plate. Timelapse of the fluorescent signal was acquired in a Flex Station 3; Control responses include IS
(control imaging solution, black traces), The signal induced by the hSERT substrate S(+)MDMA
(green trace) was blocked by pre-incubating the cells with Fluoxetine (hSERT blocker, grey
trace). Traces are plotted as mean ± SEM of n=6.

6.4.2 Potencies of the drugs using FlexStation and epifluorescence microscopy technique

We wanted to characterize how different are the apparent potencies of drugs when calcium
determinations are carried out using FlexStation or epifluorescence microscopy. An amphetamine
analog (RAD-081) was tested using hDAT-expressing cells transfected with all CaV subunits
using both assays. Dose-response curves are shown in Figure 6.13. Epifluorescence is a much
more controlled assay where calcium response from the drug can be normalized to its own control
54

and single cell analysis is possible. In FlexStation such control is impossible to obtain since drugs
are injected just once on the well and signals are collected from each well as a whole. EC50
acquired in FlexStation is about 5-fold higher than using epifluorescence microscopy.

Figure 6.13: Dose-response curves of RAD-081 using FlexStation (left) and epifluorescence
(right) measurement. hDAT cells were transfected with CaV1.2 (all subunits). Dose responses
curves of RAD-081 were in FlexStation calcium mobilization assay and in epifluorescence
microscope yielding EC50=0.79 µM and 0.17µM, respectively.

Since the FlexStation calcium mobilization system is sensitive enough to acquire doseresponse curves of compounds (substrates), we also wanted to extend our study to blockers of
monoamine transporters. N-Ethyl 4-MA is blocker of intermediate potency on hDAT [94]. 10 µM
N-Ethyl 4-MA strongly shifted the DA dose-response curve to the right (Figure 6.14B), this result
clearly show that this method can be used to identify hDAT blockers.
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Figure 6.14: Identification of an hDAT blocker using Flex Station 3 plate reader. Cells
that permanently express hDAT were co-transfected with CaV1.2 (no auxiliary subunits) and
GCamp6s coding plasmids, and were plated in a 96 well-imaging plate. Time-lapse of the
fluorescent signal was acquired in a Flex Station 3; the arrow indicates injection of drugs in
each well. (A) DA dose dependence yield EC50=6.3µM ±1.4 (B) The red trace represents the
signal of 12 control wells (DA alone). The blue trace shows 12 wells where DA (variable
concentration) was injected in combination of 10µM N-Ethyl-4-MA. The traces shown are
mean ± SEM of n=12.
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6.5

Drugs screening using Flexstation
We tested 20 newly synthetized, non-scheduled phenylethylamines (listed below) that

were provided by Dr. Richard Glennon (Medicinal Chemistry at VCU). Phenylethylamines are a
large family of organic small molecules structurally related to catecholamines [98, 99]. Many of
these compounds are active on monoamine transporters either as substrates or blockers.
1

RK-621

MW=227.73

5.1mg

2

RK-622

MW=333.21

5.7 mg

3

UMB-30

MW= 199.72 5.7mg

4

UMB-148

MW=297.90

6.3 mg

5

UMB-168

MW=287.48

5.4mg

6

UMB-178

MW=371.00

6.0mg

7

UMB-172

MW=453.53

5.2mg

8

UMB-201

MW=628.72

5.0mg

9

UMB-223

MW=615.00

6.1mg

10

UMB-208

MW=496.53

6.8mg

11

FTS-096

MW=185.65

5.5mg

12

RK-654

MW=307.86

5.3mg

13

UMB-198

MW=297.12

5.0mg

14

UMB-202

MW=306.31

5.4mg

15

UMB-209

MW=215.68

6.1mg

16

UMB-210

MW=215.68

6.5mg

17

UMB-321

MW=332.35

5.3mg

18

UMB-325

MW=332.35

5.5mg

19

UMB-328

MW=201.69

5.8mg

20

UMB-331

MW=327.37

5.2mg
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The first approach was to test these drugs in FlexStation. FlexStation is a multi-well
fluorometer plate reader with fully automated liquid transfer machinery to inject solutioncontaining drugs from compounds plate to each well of cells-containing plate. The emitted
fluorescence light is directed to the photomultiplier where light emission intensity is digitalized
and recorded. This machine can record time lapses with an acquisition frequency of ~1 Hz.
FlexStation is operating using an 8-channel pipettor that transfers reagents into consecutive
columns. In each column we run two controls – IS (row B) and either 20µM DA or 90mM K+
(row A). Each drug was tested in two columns, where rows C-E in 1st column measured lower
concentration of the drug ~10µM, and rows C-E in 2nd column measured high concentration of
the drug ~50µM. If the tested drug is a substrate, it will increase the intracellular Ca2+
concentration and will produce a fluorescent signal. If the tested drug is a blocker, there will be no
signal. Rows F-H measured the same concentration of the drug as C-D in each column,
respectively but in the presence of 20µM DA. Using this approach, we can distinguish if a
potential blocker does in fact interact with monoamine transporter. If the signal of drug + DA is
smaller than DA alone, we can assume that the drug competed with DA, thus interacted with
transporter (Figure 6.15). In wells F-H also test if the test drug is blocker but at higher
concentration, this will detect weak blockers.

58

Figure 6.15: Schematic representation of compound plate with indicated drug-solutions.
Each color (two columns) represents test of a one drug. Row A – 20µM DA (odd numbers
column) or 90mM K+ (even numbers column) control solution, row B – IS control solution, row
C-D 10µM of tested drug (odd numbers column) and 50µM (even numbers column), row F-H
10µM drug +20µM DA (odd numbers column) and 50µM drug +20µM DA (even numbers
column).

Summary of FlexStation data analysis is represented in Figure 6.16. Bar graphs represent
Ca2+ fluorescence data normalized to DA signal. Each color denotes one drug. The 1st column of
each graph is a signal acquired from the injection of 10µM drug, the 2nd column 10µM drug +
20µM DA, 3rd 50µM drug, 4th 50µM drug + 20µM DA. For drugs 7-20 all concentrations were
increased by 20%.
Drugs that induce signals in column 1st and 3rd are potential substrates. Only Drug #3 and
drug#11 induced calcium signals, whereas drug#3 was more potent than drug#11. All the rest of
the tested drugs were potential blockers with different efficacies. To validate the outcomes we
tested these compounds using epifluorescence microscopy as a secondary screening tool.
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Figure 6.16: Normalized Ca2+ fluorescence signal induced by tested dugs in hDATexpressing cells using GCaMP6s in Flex Station. Mean ± SEM signals were normalized to
20µM DA.
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6.6

Secondary drug test in epifluorescence microscope

Protocol for validating drugs using epifluorescence microscopy is shown in Figure 6.17
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Figure 6.17: Substrate protocol (A) and blocker protocol (B) of monoamine transporters
using Ca2+ imaging. Cells co-expressing hDAT and CaV1.2 were loaded with Fura2 and the Ca
signals were determined by epifluorescence microscopy. Potential substrates were exposed to
control 5µM DA (first Ca2+ peak) during 5 sec and subsequent concentrations of the tested
drug: 1µM and 10µM with 30 sec wash between were applied as depicted in the figure timeline.
For blockers, cells were exposed to pulses of 5µM DA (5sec) in the absence or presence of
1µM and 10µM of the drug as indicated in the figure timeline.
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6.6.1 Study the effect of 20 new phenylalkylamines on hSERT and hDAT
hDAT and hSERT- expressing cells underwent blocker or substrate protocol shown in
Figure 6.17. We analyzed potential substrate data by dividing the peak signal of the tested drugs
at 1µM or 10µM concentration by the control signal (5µM DA for hDAT cells and 5µM 5HT for
hSERT cells). Summary of the finding are shown in Figure 6.18. All the bars represent the
normalized Ca2+ signals. In case of substrates, Ca2+ signals were induced by the drugs and to
differentiate them from blockers they are arbitrarily represented as bars of negative values in
Figure 6.18. The larger the bar the better efficacy of the drug. In case of blockers (shown as
positive values), Ca2+ signal was induced by the control compound (either DA or 5HT) in
combination with tested drug. Bars’ values closer to 1 represent drugs that did not undergo
competition with DA (or very weak competitors), thus smaller the bar the better the blocker.
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A.

B.

Figure 6.18: Normalized Ca2+ signals in hDAT (A) and hSERT (B) expressing cells. Each
color represents effect of one drug, first and second bar correspond to signal induced by 1µM
and 10µM respectively. For substrates, bars represent Ca2+ signals achieved after applying
drug (depicted arbitrarily as negative values). For blockers bars represents the remaining Ca2+
signals of a control substrate (DA and 5HT for hDAT and hSERT expressing cells,
respectively) in the presence of the test drug (depicted as positive values) mean ± SEM, n ≥6.
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To make better comparison of the drugs from Figure 6.18, Figure 6.19 represents the same
data but in terms of potencies of the drugs. Weak blockers and weak substrates shows values
close to zero, (e.g. Drug #2 on hDAT), while strong blockers or substrate are represented by
values close to one (e.g. Drug #7 on hSERT or Drug #11 on hDAT).
hDAT
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Substrate

RK-621
RK-622
UMB-30
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UMB-321
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0.4

Blocker:
At 1uM blocks
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5uM DA signal

10uM
0.3
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0.86
0.83
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0.78
0.93
0.42
0.46
0.52
0.63
0.49
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0.34
0.61
0.81
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Figure 6.19: Values indicate normalized potencies of the tested drugs.
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Structure of the few drugs that we found the most interesting, are shown below:
HN

CH 3
CH 3

CH 3

3. UMB-030 (N-methyl 4-MA)

N-butyl 4-MA

4.UMB148 (N-octyl 4-MA)

5. UMB 168 (N-octyl 4-Methyl PEA)

7. UMB 172

9.UMB-223

10. UMB 208
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There are few characteristics of these drugs. N-methyl 4-MA is a DAT substrate with a
EC50 ~ 200nM range [94]. Increasing the length of the N-alkyl chain only by one methyl group
(N-ethyl) makes the drug a blocker with IC50 about 4uM in the Ca2+ assay. Subsequent addition of
another methyl group (N-propyl) increases the IC50 value 4 times. N-butyl further decreases
potency 3.3 times. Following this pattern, we could extrapolate that additional lengthening the
chain would decrease the affinity 12 fold for N-octyl 4-MA to about 720uM. Surprisingly N-octyl
4-MA (Drug #4) affinity on DAT is in range of 1-10µM, where 10µM completely blocks the
signal. This inverted U shape behavior suggests that additional binding moieties are potentiating
the bind of the elongated compounds. For hSERT-expressing cells increasing the length of the Nalkyl from N-methyl to N-propyl decreases the substrate EC50 from about 500nM to 2µMwhile Nbutyl 4MA was very weak on SERT [94]. Increasing the length of chain to 8 (Drug #4) make the
drug a SERT blocker with IC50 ranging from 1-10µM, where 1uM blocks the signal in 20% and
10µM by 100%. The only difference between Drug #4 and Drug #5 is additional methyl group in
alpha carbon position of N-octyl 4-MA. This modification does not change affinities on hDAT
nor hSERT. Adding an amine group at the end of the N-alkyl chain of Drug #5 yields Drug #10.
This drug shows decreased affinity on hDAT making it a very weak blocker. On the contrary, the
same amine group (Drug #10) profoundly increased affinity on hSERT almost 3 times in
comparison with Drug #5 (1µM of Drug #5 blocks 30% of the signal, while Drug#10 blocks 75%
of the signal at 1µM).
Bivalent compounds (such as Drug #7 or Drug #9) derived from monovalent drug (Drug
#10) increase affinity on hDAT about 2 times (when comparing blockage of the signal at 10µM).
On hSERT, bivalent compounds (Drug #7 and Drug #9) block the signal in 90% already at 1µM,
and are stronger than the monovalent counterpart (Drug #10) that blocks 75% at 1µM.

66

7.

Chapter seven- discussion

HYPOTHESIS 1: Monoamine transporters substrates indirectly activates voltage gated Ca2+
channels

Most if not all transporters forming the SLC6 gene family show substrate-induced inward
ionic currents when challenged near rest. In particular, for monoamine neurotransmitter
transporters, such as the electoneutral serotonin transporter or the electrogenic dopamine and
norepinephrine transporters, the charge measured during substrate flux exceeds by several fold
what is predicted by their transport rate and stoichiometry [70, 74, 100-102]. Single channel
events have been described in monoamine neurotransmitter transporters, mimicking bona fide ion
channels. The study of the 5HT-induced current I5HT of the serotonin transporter at the single
channel level reveals that Na+ is the main carrier [101]; conversely, though Cl- is not the main
carrier it can influence the channel opening rate [101]. Single channel recording in dopaminergic
neurons from C. elegans showed that Cl- is permeated through the dopamine transporter [74],
moreover dopamine transporter currents carried by Cl- ions are implicated in increasing
excitability in midbrain dopaminergic neurons [76]. We measured an increase of Na+ permeability
induced by 5HT in agreement with Petersen and DeFelice for Drosophila SERT [92], or by
S(+)MDMA in cells expressing hSERT (Fig. 4.2). Similar increase in Na+ was reported
previously in cells expressing the dopamine transporter exposed to amphetamine [103].
Interestingly, when hSERT-expressing cells are exposed to S(+)MDMA, the Na+ reaches higher
levels than when exposed to 5HT (Fig. 4.2). The set point of Na+ at rest is given by the
equilibrium between Na+ influx and efflux as described in the boundary theorem discussed for
Ca2+ but which also applies to Na+ [104]. Since there is no evidence of changes in Na+ efflux
when cells are exposed to hSERT substrates, we studied I5HT and IMDMA, which is a measure of
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Na+ influx. Long I5HT and IMDMA recordings (50 s) showed that the initial amplitudes of both
currents are identical (Fig. 5.2D), but I5HT undergoes inactivation that is less pronounced in IMDMA
(Fig. 5.2D). It is possible that the progressive accumulation of the transported 5HT in the cytosol
may decrease I5HT over time [105]; in addition, the concomitant increase of internal Na+ may
result in hSERT-mediated 5HT efflux [106, 107], decreasing the hSERT-mediated Na+ influx.
This could explains the weaker increase of intracellular Na+ concentration induced by 5HT when
compared to S(+)MDMA. The return of the signal to baseline during hSERT substrate wash out is
much slower for S(+)MDMA than for 5HT (Fig. 5.2D). This kinetic difference could be explained
by a slower repolarization for S(+)MDMA than for 5HT after wash as a result of a persistent
current in the absence of substrate described for amphetamine and amphetamine analogs as
previously reported by Dr. DeFelice’s group [108-110].
Monoamine neurotransmitter transporters coexist with Ca2+ channels, a variety of Cl− and
K+ channels, receptors, and other transporters in excitable cells. Since the relative proportions of
monoamine transporters to other current inducing membrane proteins are likely to be highly
variable among cell types, it is impossible to predict if the substrate-induced current will be
sufficient to significantly depolarize native cells. For instance K+ conductance activated by
autoreceptors (GIRK channels) [111] [112], TASK channels [113] and Ca2+ -activated K+
conductance [114] would oppose and neutralize the depolarization evoked by monoamine
transporters current. Case specific studies are required to establish resting membrane potential
changes upon monoamine transporter activation. Nevertheless, dopamine-, amphetamine- and
methamphetamine-induced DAT current increases action potential firing frequency in
dopaminergic neurons from the midbrain [76] [78], demonstrating that the depolarization evoked
by DAT activation modulates excitability in native cells. In addition, it has been shown that
dopamine induces cytosolic Ca2+ signals in cultured neurons from midbrain, cortex and
hippocampus and using pharmacological tools the
68

authors

suggest

that

monoamine

transporter-mediated depolarization could activate voltage-gated Ca2+channels [79].
In the present work, we hypothesize that the depolarization evoked by hSERT activation is
sufficient to activate voltage-gated Ca2+ channels. As a proof of concept, we tested this hypothesis
in a controlled environment such as the one provided by the heterologous expression systems
described in this study. In particular, we focused our study in the lower-threshold L-type Ca2+
channels, CaV1.3, because it is expressed in serotonergic and dopaminergic neurons and has been
shown to modulate some aspects of their function. SERT is expressed broadly through the cell
bodies and along neurite extensions in cultured serotonergic neurons. In addition, SERT is
expressed in both serotonergic fibers and cells bodies of the raphe nucleus in the brain [115]
[116]. CaV1.3 is also present in the dorsal raphe nucleus and is involved in the AMPA-mediated
dendritic serotonin release in serotonergic neurons [117], which is implicated in depression [118,
119]; thus altogether these data suggest that SERT and CaV1.3 may co-localize in the soma and
dendrites of serotonergic neurons. In dopaminergic neurons, by means of its voltage dependence
characteristics, CaV1.3 drives pace making and bursts of electrical activity [120]. In addition,
CaV1.3 activity is implicated in selective death of dopaminergic neurons in the substantia nigra in
Parkinson’s disease [121]. CaV1.3 has ∼30 mV left shift in the peak current–voltage curve
compared to the high-voltage-activated Ca2+channel, CaV2.2 (Fig. 5.3). The threshold of
activation that we measured for CaV1.3 is about −50 mV when 5mM external Ca2+ is used as the
charge carrier (Fig. 5.3), similar to that found by others [93] [122]. When we co-expressed either
CaV1.3 or CaV2.2 with hSERT in HEK239T cells, both 5HT and S(+)MDMA evoked clear
activation of CaV1.3 (Fig. 5.4 C) but not of CaV2.2 (Fig. 5.4 B) despite that, both types of cells
showed convincing Ca2+ signals induced by strong K+-depolarization (Fig. 5.4 B and C).
Since over-expression of hSERT due to transient transfection could undermine the
physiological relevance of our findings, the expression of hSERT was reduced using the Flp-In
expression system, which inserts a single copy of hSERT cDNA into the cell’s genome, by
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targeted recombination. This procedure decreased hSERT activity by 60% when compared to
transiently transfected HEK cells (Fig. 5.5 A). Despite the significant reduction in hSERT
expression, the Flp-In cells showed robust coupling between hSERT activity and CaV1.3 opening.
Moreover, concentrations as low as 100 nM are sufficient to induce Ca2+ signals implying that a
relatively low number of transporters would depolarize the membrane sufficiently to activate
CaV1.3 channels (Fig. 5.5 B and C). Accordingly, 5HT showed comparable potency for inducing
its own transport and for activating CaV1.3-mediated Ca2+ signals, implying that the electrical
coupling between hSERT and CaV channels can coexist with 5HT transport in a physiological
range of 5HT concentrations.
As mentioned above, one consequence of CaV1.3 activation is the increase of action
potential firing in excitable cells such as dopaminergic neurons [120]. Although the participation
of CaV1.3 has not been previously implicated, it was suggested that substrate-induced currents
mediated by DAT produce bursts of electrical activity in midbrain dopaminergic neurons [76]
and Ca2+ currents may be implicated in DA release mechanisms. Therefore, the electrical
coupling between a monoamine transporter and CaV1.3 described in the present study supports the
hypothesis that monoamine transporter-mediated modulation of cell excitability requires CaV1.3
activation. Further research effort is needed to assess this new hypothesis, which is beyond the
scope of the present study. The trans-activation of Ca2+ channels by the monoamine trans-porters
demonstrated in our models illustrates a new mechanism by which endogenous substrates
(neurotransmitters) or artificial substrates (amphetamine-related agents) could modulate
excitability and signaling mechanisms directed by the rise of intra-cellular Ca2+ in excitable cells.
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HYPOTHESIS 2: Electrical coupling between Ca2+ channels and monoamine transports can
discriminate substrates and blockers of the transporters

The Ca2+ assay described here can generate dose-response curves of drugs that interact
with monoamine transporters [94, 123] [89]. This new method is based on the electrical properties
of monoamine transporters; the inward current induced by substrates of transporters can
depolarize the plasma membrane and activate voltage-gated channels. The indirect opening of
Ca2+ channels induced by substrates of monoamine transporters generate tight-coupled Ca2+
signals that can be used to identify unclassified substrates. Although blockers do not generate
inward current and produce no Ca2+ signal, they still can be identified by inhibiting a Ca2+ signal
induced by a known substrate (Fig. 6.1).
Neurotransmitter uptake and release studies in synaptosomes, is a well-accepted technique
to identify and discriminate between substrates and blockers of monoamine transporters [51].
When the same set of drugs were tested using the new Ca2+ assay and compared to the outcomes
using synaptosomes, the results of both techniques were highly correlated. The EC50 for several
substrates on DAT, NET and SERT showed a coefficient correlation R=0.96 among these
techniques [94]. Similarly, IC50 testing several blockers on the three transporters yield a perfect
correlation, R=1.00.
Although the study of the release potential of test drugs using the synaptosomes method is
used to distinguish between substrates and blockers of MATs, one problematic aspect of these
experiments is that some potent uptake inhibitors can produce low-efficacy efflux of radiolabeled
pre-loaded drugs (e.g. [3H]MPP+) [124]. Still it is not clear whether drugs that produce partial
release that were discovered using the synaptosome are actually substrates of transporters. When
partial releasers were evaluated in the Ca2+ assay and TEVC, these compounds do not generate
inward current, suggesting that partial releasers are actually blockers. One possible explanation
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for these discrepancies is that partial releasers may induce slower transitions of the transporters
that may not be fast enough to generate inward current. This is possible taking into account that
the synaptosome experiments are performed in a time scale in the tens of minutes, whereas the
electrophysiological determinations are done in few seconds. These results clearly suggest that
substrates and blockers of MATs are not part of binary states, and can be rather depicted as a
continuum where it is possible to find compounds with intermediate behavior.
Since synaptosomes are isolated from brain tissue, the type of transporter studied is
restricted to the origin of this tissue, in most cases the experiments are performed in rat
synaptosomes. Studies show that species from which monoamine transporters come from can
change interaction of drugs and transporters. Most prominent examples are different effects of
cocaine on drosophila and human dopamine transporters [125] and higher sensitivity of inhibitors
on human SERT than on chicken SERT [126]. The Ca2+ method described here has the advantage
that transporters from any origin can be used. In all the experiments performed here, we used the
human variant of the transporters. In addition, mutations of transporters can also be expressed to
study interactions between drugs and specific transporters’ residues. Additionally, Ca2+ assay can
provide drug profiling on all three monoamine transporter tasks that, although is possible to
perform using synaptosomes, is largely restricted in TEVC technique when hDAT, hNET and
hSERT are meant to be expressed in Xenopus laevis oocytes. While only hSERT can be
expressed efficiently in oocytes, hDAT shows expression variability and hNET is not expressed at
all [127]. Thus, the Ca2+ technique described here provides a reliable mechanism to study the
electrophysiological signature of drugs on the three transporters.
In summary, Ca2+ assay can help overcome some obstacles found in synaptosome and
TEVC assays and can be used either as substitution of these techniques or as source of additional
information about the electrophysiological signature of tested drugs and it constitutes a new
quantitative analysis of substrate/blocker drug profiles on monoamine transporters.
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Our next proposed approach was to strategize rapid evaluation of drug-effect profiles at
monoamine transporters. Monoamine transporters are primary targets for drugs of abuse and also
drugs used in treatment of mental diseases. Often, the correlation between these two groups lies in
the affinity and selectivity of the drug on the transporters. Current methods to evaluate the activity
profile of drugs on monoamine transporters are too slow to efficiently proliferate drug
development. Synaptosome release assay, although helpful in distinguishing blockers and
substrates, has low screening throughput, is laborious and time consuming, also since it uses the
neuronal membrane it requires usage of agents that block effects of tested drugs on other targets.
Another approach, such as TEVC in frog oocytes-expressing MATs, although measuring direct
effect of drugs on monoamine transporters is not appropriate for rapid screening. Other technique
suitable for high throughput screening, for instance the competition of high affinity radiolabeled
MAT blockers has some limitations. It can oversight the identification of relevant substrates that
normally have lower affinity than blockers on transporters. Newer approaches use fluorescent
substrates able to mimic neurotransmitter interactions with transporters that are being uptaken
into the cells resulting in increase of intracellular fluorescence. One of the techniques employ
fluorescent substrate ASP+ (4-(4-(dimethylamino)styrl)-N-methylpyridinium) that was developed
later for microplate-based high-throughput screening for hSERT function [128]. Measuring ASP+
uptake as fluorescence non-isotopic tool to characterize monoamine transporter occurs being a
practicable and reliable approach since data shows very similar results to those done by traditional
radiometric uptake assays [129]. Studies show also novel fluorescence-based neurotransmitter
transporter uptake assay kit that allows for examining transport activity of DAT, NET and SERT
and characterizes compounds in a high-throughput [130]. Unlike the radiolabeling-based method,
fluorescence substrates allow for real-time monitoring, direct visual assessment of preparation in
96/384/1536-wells as well as temperature- controlled fluorescence plate reader that also
73

allows for automated liquid dispensation. The use of fluorescent substrates, even though can
identify and characterize the potency of drugs on monoamine transporters, can only test for
uptake competitors where substrate/blocker discrimination is not possible [130]. In general terms,
a big limitation of all competition HTS assays is that they cannot discriminate if test compounds
are blockers or substrates of transporters, they can only identify monoamine transporters ligands.
The new Ca2+ assay described here, is a fluorescence-based technique that is amendable for HTS
and it can easily discriminate substrates from blockers of monoamine transporters in a matter of
seconds. Initially our fist approach was to use epifluorescence microscopy in combination with a
temperature-controlled automatic perfusion system to profile drugs with high precision. In an
effort to further improve this approach, we implemented several optimization steps, plus the use
of FlexStation 3 plate reader to increase the rate of drug testing and as preliminary approach
toward optimization for HTS.
To distinguish whether FlexStation is faster than epifluorescence microscopy we are
providing the approximate time required for performing experiments in each assay (see the table
below). When comparing the time required to perform one-session experiment (from preparing
the plate to analysis) FlexStation assay is 2.8 times faster than epifluorescence microscope
(569min/202min). When comparing the number of wells from which data were acquired during
that time, FlexStation assay allows for examining 2.6 more wells than epifluorescence microscope
(96well/36wells). Overall, taking to account all the steps, assessing one well in FlexStation takes
approximately 2 minutes (202min/96wells), while in epifluorescence microscope almost 16
minutes (569min/36wells), so using the FlexStation technique improves time efficiency 8 times.

74

Time

Epifluorescence microscope

FlexStation

Preparation Coating 36 wells with Matrigel – Coating 96 wells with Collagen – 5
of the plate 5min + 20 min incubation = 25min

min + 25 min incubation in RT,

– coating

suction of the solution and drying:
15min min, wash with PBS, drying
15min = 1h

Plating the 4min

7min

cells
Preparation Loading the cells with Fura 2 + IS, Changing solution from DMEM to IS
for

the each

experiment

column

has

to

be

done = 5min

separately, waiting 25 min at 37ºC =
30min

Preparation 30min
of

30min

the

drugs
solutions
Acquiring

36 wells- 6h manual handling

96wells- 40min, FlexStation work

data
Analysis

Picking the cells’ ROI + analysis Analysis using temple – 1h
using temple – 2h

Total time

25+4+30+30+6*60+2*60

= 60+7+5+30+40+60 = 202min~3.4h

569min~9.5h (this is for 36 wells)
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(this is for 96 wells)

When the same monoamine transporter ligands are tested using the epifluorescence
microscope or the FlexStation, the potencies to generate Ca2+ signals differ significantly among
techniques. A good example is the amphetamine analog RAD-081 that showed EC50 of 0.17µM
and 0.79µM when tested using epifluorescence microscopy or the FlexStation, respectively.
Similarly, dopamine yielded EC50 of 0.92 µM (microscopy) [123] compared to 6.4µM (Flex
Station). In general, potencies to generate Ca2+ signals differ between both techniques about 5 to
10 times. One important aspect that could account for this difference is the diffusion time of the
test drug to encounter the cells. We should consider that in epifluorescence microscopy cells
undergo constant perfusion, and the perfusion outlet is placed very near cells; thus passive
diffusion of drug particles to encounter cells is not a limiting step. In the FlexStation, the drugs
are not subjected to perfusion or agitation, the only external forces that drive particle motion are:
the injection of 80µl of concentrated sample to the well containing in 50µl of physiological
solution, and the passive diffusion of the drug into the solution to equilibrate the final
concentration in the well. The difference in speed of how cells encounter particles of the test drug
between these two techniques is evident from the kinetics to generate Ca2+ signals (dose response
acquire in epifluorescence microscope show much steeper curve as shown in Fig. 6.8 A, in
comparison to the FlexStation date in Fig. 6.9 B). Of course, the depolarization of the plasma
membrane, that is what drives the opening of the Ca2+ channel, is proportional to the number of
transporters activated by the substrate in each moment. Thus, it is expected that the diffusional
effect in FlexStation will decrease the depolarization induced by a theoretical concentration of
drug because drug particles take more time to encounter the cells compared to perfused cells. This
would explain the right shift in the apparent EC50 in FlexStation compared to the fluorescent
microscopy assays.
The other possible explanation for the differences in apparent potencies in FlexStation vs.
epifluorescence microscopy is related to how the signals are acquired in both techniques. In
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FlexStation the Ca2+ signal is obtained from the whole well by a photomultiplier, while in the
epifluorescence microscope Ca2+ increase is acquired by an Electron-Multiplying ChargeCoupled Device (EMCCD) camera that gives 2D information where the response of each
individual cell can be analyzed. In the case of the epifluorescence microscopy, only cells that
were transfected and responded to a control (e.g. DA in the case of cells expressing hDAT) were
picked for analysis. Quality standards are taken into consideration for each individual cell
analyzed, such as low resting Ca2+ level and the absence of Ca2+ waves or cell detachments during
the experiment. This way, it can be assured that the Ca2+ signals included in the analysis are a
result of the experiment and not an experimental artifact. In FlexStation, such a control cannot be
achieved, since the Ca2+ signal is measured in a well as a whole. It is possible, that in some wells
over-crowdedness and cell detachments may produce Ca2+ oscillations that may add to the overall
signal and contributing in some extent to the variability of the data.
Another factor that may explain the shift of the EC50 between these two methods is
differences in the limit of detection of the detectors. Although unlikely, if the photomultiplier has
less sensitivity than the EMCCD camera to detect the fluorescence signal, responses at lower
concentrations will be penalized in the FlexStation, explaining the right shift in the EC50 values.
One of the important features of the Ca2+ assay described in this work is that it can
discriminate between substrates and blockers of monoamine transporters. When the outcomes of
this technique using both approaches (FlexStation and the fluorescence microscope) were
compared, in almost all cases drugs that showed an interaction on the transporter in the
FlexStation (as either substrate or blocker) corresponded to the effect observed in the fluorescence
microscope (Fig. 6.15 and 6.18). Some drugs like Drug #8 UMB-201 show some differences, in
epifluorescence microscopy, this drug show features of a moderate blocker that blocks 85% of a
DA signal at 10µM concentration. On the other hand, FlexStation data show that this drug is a
substrate at 61µM. In this case, a closer look at the protocol in each of the techniques has to be
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taken into consideration. FlexStation measures Ca2+ signal for a much longer time than
epifluorescence microscope. In the epifluorescence microscope the exposure of the drug takes
place within 5sec for substrates and 30 sec for blockers, while in FlexStation cells undergo
exposure of a drug for about 2min. To test the possibility that this drug could induce Ca2+ signals,
further studies involving long exposure of this drug to the cells must be conducted in
epifluorescence microscopy. Overall, although FlexStation has some disadvantages, it can
definitely be used as a first approach to distinguish between substrates and blockers of
monoamine transporters.
In an effort to optimize the output of the signal in the FlexStation several Ca2+ sensors
were evaluated by comparing three parameters: (1) the dynamic range of the signal, defined as
the maximal fluorescence minus the basal fluorescence upon stimulation with saturating
concentration of positive standard, (e.g. amphetamine for hDAT-expressing cells); (2) sensitivity,
defined as the maximal slope in the dose response curve; (3) signal to noise ratio, defined as the
dynamic range divided by the standard deviation of the reading. A standard Ca2+ sensor, Fluo-4
was compared to the ultrabright genetically encoded Ca2+-sensing fluorescent proteins. Ca2+ dyes
with different affinities for Ca2+ have been used broadly for studying intracellular Ca2+ signals in
excitable cells. Neuronal Ca2+ signals that are characterized by a sometimes fast Ca2+ dynamic
and low amplitude [131] require ultrasensitive and fast Ca2+ indicators. Fluorescence studies done
in rat hippocampal neurons provide insight into sensitivity, dynamic rage and kinetics of
GCaMPs. Using mutagenesis, improved versions of GCaMPs have been described along the
years.
As we saw in Fig. 6.6 GCaMP6s (Kd=144nM with dynamic range (Fmax/Fmin)=63.2±3.1
and Koff=1.12 s-1) has robust Ca2+ signal and the widest dynamic range among all the dyes that
were tested. The potency of a known substrate to generate Ca2+ signals using GCamP6s or Fura-2
as Ca2+ indicators was very similar, thus, GCamP6s can be used as a surrogate of Fura-2
78

to test potency of drugs on transporters. One disadvantage of GCamP6s is that, because its high
affinity to Ca2+, the signal can be easily saturated and the efficacy of drugs could not be resolved
properly.
For the type of studies that predict low vs. high efficacy of the drugs, GCaMPf
(Kd=375nM, dynamic range Fmax/Fmin = 52, Koff=3.9 s-1) [95] can be used. It has fast kinetics,
which produce robust Ca2+ signals but due to the fast binding and unbinding properties has a
lower saturation range. Since the higher affinity dye GCaMP6s will saturates more easily than the
lower affinity dye GCaMP6f, choosing between these two dyes might work to resolve efficacies
of compounds that produce different levels of depolarization, which was shown on the example of
DA and Amph signals in Fig. 6.6. What is also worth mentioning, GCaMPCAAX – the brightest
version of GCaMP but tethered to the membrane, shows a very low dynamic range (Fig. 6.6). One
possibility is that these proteins might be expressed in the lower amount due to more complex
protein sorting mechanisms to the plasma membrane.
Detection of drugs that interact with monoamine transporters using Ca2+ channels is novel
methodology and can be used in drug discovery. Although the primary reason to develop our
method was to study the pharmacology of monoamine transporters, it is possible to use this
methodology to study any membrane protein that induces an inward current. One example can be
serotonin-gated 5-HT3 receptor, present in the central and peripheral nervous system. This ligandgating ion channel regulates mood and appetite, and drugs that interact with this receptor are used
for treatment of depression [132]. Most importantly, 5-HT3 agonists play a crucial role in
suppressing vomiting side effects induced by chemotherapy and radiotherapy, thus discovering
selective agonist for 5-HT3 has been a great interest in cancer drug discovery research [133].
Activation of 5-HT3 enhances the release of few neurotransmitters such as dopamine,
cholecystokinin and GABA [134]. It was shown that this cation-selective channel [135] causes
neuronal depolarization and excitatory response in neurons [136] since current is carried
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mostly by sodium and potassium ions [137]. Application of 3µM 5-HT, tested in isolated rat
nodose ganglion neurons, induced inward current that ranged from 40-60pA [138].
Another membrane protein, which pharmacology could be explored using our method is
Organic Anion Transporter (OAT). This transporter plays a crucial role in renal function [139] . It
was shown that OAT plays a role in hepatic uptake of 5-HT, while xenobiotics can alter 5-HT
elimination [140]. Electrophysiological studies show that Para Aminohippuric Acid (PAH), a
typical substrate of OAT [141], induces an inward current. The most common method to evaluate
substrates for these transporters is using radiolabeled PAH competition assay. However, these
studies cannot prove if the tested compound is translocated. One of the first methods to test
translocation of substrates was electrophysiological study [142] where substrate-induced currents
were conducted to distinguish structure/function relationship of the OAT. Increase of membrane
conductance in flounder Renal Organic Anion Transporter (fROAT) expressing oocytes were
proportional to net charges translocated though fROAT. Current clamp experiment performed in
oocytes expressing fROAT showed a small depolarization of 4mV induced by 100uM PAH from
a resting potential of -40mV. Holding potential at -60mV in voltage clamp investigation showed
inward current of 23nA after applying PAH [142]. Even such small currents can be detected in
our Ca2+ epifluorescence microscopy method, since currents of comparable amplitude are
recorded in oocytes expressing monoamine transporters. Ca2+ assay would be a great tool in
expanding the pharmacology of mentioned protein where their activity is linked to membrane
depolarization.
New Psychoactive Substances (NPS) are substances that imitate already existing drugs of
abuse, such as MDMA or cannabis. [143] They are manufactured as new “legal” substances and
can be purchased online hence earning name “legal high”. They are divided into 4 categories:
stimulants, cannabinoids, hallucinogens and depressants. In Europe, the European Monitoring
Center of Drugs and Drug Addiction monitor over 560 NPS compounds; stimulant and
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synthetic cannabinoids are the most popular and cause the highest clinical encounter. Legislations
regarding NPS differ in each country. In the UK, it is now illegal to sell of distribute them while
possession is not. The only information about the effect on NPS comes from case reports and case
series. One example of NPS is 4-Methylamphetamine (4-MA) stimulant and appetite suppressant
[144] that also causes fatal intoxication [145]. From a pharmacological point of view, it is a
nonselective transporter substrate with affinities equal 44nM, 22nM and 53nM on DAT, NET and
SERT respectively [146]. Recent studies investigated the effect of 4-MA analogs where amine
group was substituted with longer (up to 4 carbon) side chain [94]: N-methyl, N-ethyl, N-propyl
and N-butyl. The studies showed few interesting findings regarding increasing the length of the
N-alkyl chain first – it decreases inhibitory potencies on monoamine transporters, second – loss
substrate activity on DAT (N-alkyl chain greater than N-methyl group) and NET (N-alkyl chain
greater than N-ethyl group) causing loss of rewarding effect of these compounds. The compound
with the longest studied chain N-butyl was a very weak substrate at SERT and a very weak
blocker at DAT according to TEVC data. In Ca2+ assay (hSERT) N-butyl 4-MA behaved also as a
weak substrate with a potency too small to be clearly determined, while on hDAT the IC50 was
about 60µM [94]. What can be concluded from these findings is that increasing the N-alkyl side
chain on 4-MA weakens the effect on DAT and SERT. Surprisingly one of the compound that we
tested, Drug #4 (N-octyl 4-MA) (Fig. 6.19) with 8-carbon length, showed resuscitated blocker
activity on DAT and SERT with IC50~5uM (where 10µM drug blocks 100% of the signal).
Furthermore, additional bivalent drug (Drug #7) derived from monovalent drug (Drug#10)
increases affinity on DAT about 5 times when comparing blockage of the signal at 10uM. One of
the explanations might be simultaneous binding to multiple sites on monoamine transporters.
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It has been shown that designing bivalent compounds produces selective opioid, serotonin
and muscarinic receptor ligands with one order of magnitude higher affinity compared to its
monovalent parent ligand [147] [148] [149]. This phenomenon cannot simply be explained by
increasing concentrations of monovalent ligand but rather can be understood in the
thermodynamic energy landscape of the ligand-protein interaction. In this system cooperative
binding of the ligand that is tethered to the additional ligand lower the entropy of the
ligand/protein complex. [150] Also, in relation to monoamine transporters creating bivalent
pentamethyl spacer-linker yield 2300-fold higher inhibition activity [151]. Another study showed
that two phenyltropane moieties with 6-8 carbon linker are a potent inhibitor of DAT [152].
Furthermore, two substrate-like phenylalkylamine linked by an aliphatic spacer achieved up to
82-fold gain in inhibition of [3H] CFT binding compared with monovalent equivalent. Modeling
and docking studies of the most potent bivalent ligands confirmed two discrete substrate-binding
domains [153]. To test the possibility that our tested drug indeed binds to two binding sites, or
that one site plays a role of allosteric modulator, further studies involving mutagenesis have to be
conducted.
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